Integer (ITGR) 10-K 22 Feb 22 2021 FY Annual report Financial data

Cover

Cover - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Feb. 16, 2022	Jul. 02, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	1-16137
Entity Registrant Name	INTEGER HOLDINGS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	16-1531026
Entity Address, Address Line One	5830 Granite Parkway,
Entity Address, Address Line Two	Suite 1150
Entity Address, City or Town	Plano,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75024
City Area Code	214
Local Phone Number	618-5243
Title of 12(b) Security	Common Stock, Par Value $0.001 Per Share
Trading Symbol	ITGR
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 3.1
Entity Common Stock, Shares Outstanding (in shares)		33,097,540
Documents Incorporated by Reference	Portions of the following document are specifically incorporated by reference into the indicated parts of this report: Document Part Proxy Statement for the 2022 Annual Meeting of Stockholders Part III, Item 10 “Directors, Executive Officers and Corporate Governance” Part III, Item 11 Part III, Item 12 Part III, Item 13 Part III, Item 14
Entity Central Index Key	0001114483
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2021
Auditor Information [Abstract]
Auditor Name	Deloitte & Touche LLP
Auditor Location	Williamsville, New York
Auditor Firm ID	34

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 17,885	$ 49,206
Accounts receivable, net of provision for credit losses of $0.1 million and $0.2 million as of December 31, 2021 and 2020, respectively	182,310	156,207
Inventories	155,699	149,323
Refundable income taxes	4,735	2,087
Contract assets	64,743	40,218
Prepaid expenses and other current assets	27,610	15,896
Total current assets	452,982	412,937
Property, plant and equipment, net	277,099	253,964
Goodwill	924,704	859,442
Other intangible assets, net	807,810	757,224
Deferred income taxes	5,711	4,398
Operating lease assets	70,053	45,153
Other long-term assets	43,856	38,739
Total assets	2,582,215	2,371,857
Current liabilities:
Current portion of long-term debt	15,250	37,500
Accounts payable	76,859	51,570
Income taxes payable	725	1,847
Operating lease liabilities	9,862	8,431
Accrued expenses and other current liabilities	56,933	56,843
Total current liabilities	159,629	156,191
Long-term debt	812,876	693,758
Deferred income taxes	171,505	182,304
Operating lease liabilities	59,767	37,861
Other long-term liabilities	23,741	30,688
Total liabilities	1,227,518	1,100,802
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding as of December 31, 2021 and 2020	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,063,336 and 32,908,178 shares issued and outstanding as of December 31, 2021 and 2020, respectively	33	33
Additional paid-in capital	713,150	700,814
Retained earnings	614,324	517,516
Accumulated other comprehensive income	27,190	52,692
Total stockholders’ equity	1,354,697	1,271,055
Total liabilities and stockholders’ equity	$ 2,582,215	$ 2,371,857

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Allowance for doubtful accounts	$ 0.1	$ 0.2
Stockholders’ equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	100,000,000	100,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	33,063,336	32,908,178
Common stock, shares outstanding (in shares)	33,063,336	32,908,178

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Sales	$ 1,221,079	$ 1,073,442	$ 1,258,094
Cost of sales	884,109	787,735	903,084
Gross profit	336,970	285,707	355,010
Operating expenses:
Selling, general and administrative	141,418	109,006	138,695
Research, development and engineering	51,985	48,468	46,529
Other operating expenses	7,856	7,621	12,151
Total operating expenses	201,259	165,095	197,375
Operating income	135,711	120,612	157,635
Interest expense	31,628	38,220	52,545
(Gain) loss on equity investments, net	3,143	(5,337)	475
Other (income) loss, net	(123)	1,522	(578)
Income from continuing operations before taxes	101,063	86,207	105,193
Provision for income taxes	8,043	8,949	13,975
Income from continuing operations	93,020	77,258	91,218
Discontinued operations:
Income from discontinued operations before taxes	4,931	0	5,296
Provision for income taxes	1,143	0	178
Income from discontinued operations	3,788	0	5,118
Net income	$ 96,808	$ 77,258	$ 96,336
Basic earnings per share:
Income from continuing operations (in dollars per share)	$ 2.82	$ 2.35	$ 2.80
Income from discontinued operations (in dollars per share)	0.11	0	0.16
Basic earnings per share (in dollars per share)	2.93	2.35	2.95
Diluted earnings per share:
Income from continuing operations (in dollars per share)	2.80	2.33	2.76
Income from discontinued operations (in dollars per share)	0.11	0	0.15
Diluted earnings per share (in dollars per share)	$ 2.91	$ 2.33	$ 2.92
Weighted average shares outstanding:
Basic (in shares)	32,993	32,845	32,627
Diluted (in shares)	33,258	33,113	33,037

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Comprehensive Income
Net income	$ 96,808	$ 77,258	$ 96,336
Other comprehensive income (loss):
Foreign currency translation gain (loss)	(27,826)	34,907	(7,900)
Net change in cash flow hedges, net of tax	2,105	(2,052)	(4,580)
Defined benefit plan liability adjustment, net of tax	219	(151)	(536)
Other comprehensive income (loss), net	(25,502)	32,704	(13,016)
Comprehensive income	$ 71,306	$ 109,962	$ 83,320

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net income	$ 96,808	$ 77,258	$ 96,336
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	81,369	79,324	77,895
Debt related charges included in interest expense	6,954	4,774	7,772
Stock-based compensation	16,185	9,163	9,294
Non-cash (gains) charges related to customer bankruptcy	(348)	554	21,695
Non-cash lease expense	8,235	7,810	7,443
Non-cash (gain) loss on equity investments	3,143	(5,337)	475
Contingent consideration fair value adjustment	133	(2,000)	0
Other non-cash (gains) losses	2,202	600	(162)
Deferred income taxes	(10,270)	(6,966)	(10,285)
Gain on sale of discontinued operations	0	0	(4,974)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(17,539)	38,153	(6,976)
Inventories	4,700	18,441	3,724
Prepaid expenses and other assets	(2,409)	(864)	(6,293)
Contract assets	(24,923)	(15,451)	(24,767)
Accounts payable	19,525	(9,055)	1,887
Accrued expenses and other liabilities	(22,984)	(10,721)	(2,744)
Income taxes payable	(4,115)	(4,342)	(4,962)
Net cash provided by operating activities	156,666	181,341	165,358
Cash flows from investing activities:
Acquisition of property, plant and equipment	(53,463)	(46,832)	(48,198)
Purchase of intangible asset	0	(4,607)	0
Proceeds from sale of property, plant and equipment	443	82	28
Purchase of equity investments	0	0	(417)
Proceeds from sale of discontinued operations	0	0	4,734
Acquisitions, net	(217,978)	(5,219)	(15,009)
Net cash used in investing activities	(270,998)	(56,576)	(58,862)
Cash flows from financing activities:
Principal payments of term loans	(741,786)	(87,500)	(111,500)
Proceeds from issuance of term loans	818,250	0	0
Proceeds from revolving credit facility	82,300	185,000	34,000
Payments of revolving credit facility	(63,000)	(185,000)	(39,000)
Proceeds from the exercise of stock options	743	3,263	3,242
Payment of debt issuance costs	(8,139)	(515)	(1,385)
Tax withholdings related to net share settlements of restricted stock awards	(4,592)	(3,820)	(3,283)
Contingent consideration payments	(1,621)	0	0
Principal payments on finance leases	(169)	(6)	0
Net cash provided by (used in) financing activities	81,986	(88,578)	(117,926)
Effect of foreign currency exchange rates on cash and cash equivalents	1,025	(516)	(604)
Net increase (decrease) in cash and cash equivalents	(31,321)	35,671	(12,034)
Cash and cash equivalents, beginning of year	49,206	13,535	25,569
Cash and cash equivalents, end of year	$ 17,885	$ 49,206	$ 13,535

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock and additional paid-in capital	Treasury stock	Retained earnings	Retained earningsCumulative Effect, Period of Adoption, Adjustment	Accumulated other comprehensive income
Total stockholders’ equity, beginning balance at Dec. 28, 2018	$ 1,060,493	$ 691,116	$ (8,125)	$ 344,498	$ (576)	$ 33,004
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		641
Stock-based compensation		9,294
Treasury shares purchased			(2,961)
Treasury shares reissued			2,277
Net income	96,336			96,336
Other comprehensive income (loss)	(13,016)					(13,016)
Total stockholders’ equity, ending balance at Dec. 31, 2019	1,152,488	701,051	(8,809)	440,258		19,988
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		(9,367)
Stock-based compensation		9,163
Treasury shares reissued			8,809
Net income	77,258			77,258
Other comprehensive income (loss)	32,704					32,704
Total stockholders’ equity, ending balance at Dec. 31, 2020	1,271,055	700,847	0	517,516		52,692
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		(3,849)
Stock-based compensation		16,185
Net income	96,808			96,808
Other comprehensive income (loss)	(25,502)					(25,502)
Total stockholders’ equity, ending balance at Dec. 31, 2021	$ 1,354,697	$ 713,183	$ 0	$ 614,324		$ 27,190

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition to medical technologies, the Company develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. Basis of Presentation and Principles of Consolidation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20 “Discontinued Operations” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations. The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&O Product Line were reported in the Medical segment. Refer to Note 18 “Segment and Geographic Information,” for additional information on the Company’s reportable segments. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates. Risks and Uncertainties Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) created significant uncertainty and worldwide economic disruption. Specific impacts to the Company’s business included and continue to include labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, restrictions on associates’ ability to travel or work, and delays in shipments to and from certain countries. The extent to which COVID-19 will continue to impact the Company’s operations depends on future developments, which remain highly uncertain and difficult to predict, including, among others, the duration of the outbreak, the effectiveness and utilization of vaccines for COVID-19 and its variants, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise that the Company is not aware of currently. Any prolonged material disruption of the Company’s labor force, suppliers, manufacturing, or customers could materially impact its consolidated financial position, results of operations or cash flows. Cash and Cash Equivalents Cash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Revenue from Contracts with Customers” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks. Trade Accounts Receivable and Provision for Current Expected Credit Losses The Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred. In 2020, the Company wrote-off $2.3 million of outstanding receivables that were previously reserved for as of December 31, 2019, in connection with a customer bankruptcy in the fourth quarter of 2019. Supplier Financing Arrangements The Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale. During the years ended December 31, 2021 and December 31, 2020, the Company sold and de-recognized accounts receivable and collected cash of $116.1 million and $73.3 million, respectively. The costs associated with the supplier financing arrangements were not material for the years ended December 31, 2021 and December 31, 2020. Inventories Inventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory. In connection with a customer bankruptcy in the fourth quarter of 2019, the Company wrote-down inventory by $19.0 million. Leases The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating. The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Finance lease assets and corresponding liabilities are included in Other long-term assets, Accrued expenses and other current liabilities, and Other long-term liabilities, respectively, on the Consolidated Balance Sheets. Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments. The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs. Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses. The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14 “Leases” contains additional information on the Company’s leases. Property, Plant and Equipment (“PP&E”) PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e . the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows: Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment. Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market. Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations. Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements. Acquisitions The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) All direct acquisition-related costs are expensed as incurred and are recognized as a component of Other operating expenses. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. Contingent Consideration In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis. In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Other operating expenses in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements. Goodwill Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis. If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) The Company completed its annual goodwill impairment test as of December 31, 2021 and determined, after performing a qualitative review of its Medical reporting unit, that it is more likely than not that the fair value of the Medical reporting unit exceeds its carrying amount. Accordingly, there was no indication of impairment and the quantitative goodwill impairment test was not performed for the Medical reporting unit. The Company bypassed the qualitative analysis for its Non-Medical reporting unit and performed a quantitative analysis. The fair value of the Non-Medical reporting unit exceeded its carrying amount as of December 31, 2021. Other Intangible Assets Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets. The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method. Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets. Equity Investments The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows: • Non-marketable equity securities are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs. • Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value. Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of our receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery. The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17 “Financial Instruments and Fair Value Measurements” for additional information on the Company’s equity investments. Debt Issuance Costs and Discounts Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts. Income Taxes The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized. The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&A”) expenses. The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Derivative Financial Instruments The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value . The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, if so, the reason for holding it. The Company’s use of derivative instruments is generally limited to cash flow hedges of certain interest rate risks and minimizing foreign currency exposure on foreign currency transactions, which are typically designated in hedging relationships, and intercompany balances, which are not designated as hedging instruments. Under master agreements with the respective counterparties to our derivative contracts, subject to applicable requirements, we have the right of set-off and are allowed to net settle transactions of the same type with a single net amount payable by one party to the other. Gains and losses on cash flow hedges are recorded in Accumulated Other Comprehensive Income in the Consolidated Balance Sheets until the underlying transaction is recorded in earnings. When the hedged item is realized, gains or losses are reclassified from Accumulated Other Comprehensive Income (“AOCI”) to the Consolidated Statement of Operations on the same line item as the underlying transaction. In the event the forecasted transactions do not occur, or it becomes probable that they will not occur, the Company reclassifies any gain or loss on the related cash flow hedge to earnings in the respective period. Cash flows related to these derivative financial instruments are included in cash flows from operating activities. Foreign currency contracts not designated as hedging relationships are recorded at fair value in Accrued expenses and other current liabilities in the Consolidated Balance Sheets and resulting gains or losses are recorded in the Consolidated Statement of Operations. Revenue Recognition The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year. The Company evaluates revenue recognition in contracts with customers as performance obligations are satisfied and as the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to

Business Acquisition

Business Acquisition	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
BUSINESS ACQUISITIONS	BUSINESS ACQUISITIONS 2021 Acquisition On December 1, 2021, the Company acquired 100% of the equity interests of Oscor Inc., Oscor Caribe, LLC and Oscor Europe GmbH (collectively “Oscor”), privately-held companies with operations in Florida, the Dominican Republic and Germany that design, develop, manufacture and market a comprehensive portfolio of highly specialized medical devices, venous access systems and diagnostic catheters and implantable devices for a cash purchase price of $220.4 million, of which $2.6 million is net cash acquired subject to payment in connection with working capital and other closing adjustments. Serving the Company’s current markets, Oscor broadens the Company’s product portfolio, expands its research and development capabilities, and adds low-cost manufacturing capacity. The Company used proceeds from its Senior Secured Credit Facilities to fund the acquisition. See Note 8 “Debt” for additional information. Oscor is included in the Company’s Medical segment. The Oscor acquisition was structured as a stock purchase, however the parties agreed to coordinate the election of Section 338(h)(10) of the Internal Revenue Code relative to this transaction for tax purposes. Therefore, the excess purchase price over the fair value of net assets acquired was recorded as goodwill, which will be amortized over 15 years for income tax filing purposes. The Company has provisionally estimated fair values for the assets purchased, liabilities assumed and purchase consideration as of the date of the acquisition. The determination of estimated fair value required management to make significant estimates and assumptions based on information that was available at the time the consolidated financial statements were prepared. The amounts reported are considered provisional as the Company is completing the valuations that are required to allocate the purchase price in areas such as property and equipment, intangible assets, lease-related assets and liabilities, deferred taxes and goodwill. As a result, the allocation of the provisional purchase price may change in the future, which could be material. The preliminary purchase price allocation was as follows (in thousands): Fair value of net assets acquired Current assets (excluding inventory) $ 12,148 Inventory 12,212 Property, plant and equipment 17,977 Goodwill 77,887 Intangible assets 105,300 Operating lease assets 15,142 Other noncurrent assets 695 Current liabilities (8,875) Operating lease liabilities (12,044) Fair value of net assets acquired $ 220,442 The preliminary fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations. The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions. (2.) BUSINESS ACQUISITIONS (Continued) Current Assets and Liabilities The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities. The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the income approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance for these remaining efforts. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $1.0 million. Property, Plant and Equipment The fair value of PP&E acquired was estimated by applying the cost approach for personal property and leasehold improvements. The cost approach was applied by developing a replacement cost and adjusting for economic depreciation and obsolescence. Leases The Company recognized operating lease liabilities and operating lease right-of-use assets for office and manufacturing facilities in the U.S., Dominican Republic, and Germany in accordance with ASC 842, Leases . Additionally, the Company recorded favorable lease terms associated with the operating leases in the U.S. of $3.1 million. The favorable lease terms were recorded as an increase to the ROU lease asset. Goodwill The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including the value of Oscors’s highly trained assembled work force and management team, the incremental value resulting from Oscor’s industry leading capabilities and services to OEMs, enhanced synergies, and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the acquisition was allocated to the Medical segment and is deductible for tax purposes. Intangible Assets The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Weighted Average Discount Rate Customer lists $ 73,800 20.0 9.5% Technology 15,200 15.0 9.5% Tradenames 16,300 20.0 9.5% Customer Lists - Customer lists represent the estimated fair value of contractual and non-contractual customer relationships Oscor had as of the acquisition date. The primary customers of Oscor include large original equipment manufacturers in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The estimated useful life of the existing customer base was based upon the historical customer annual attrition rate of 5%, as well as management’s understanding of the industry and product life cycles. Technology - Technology consists of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by Oscor and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate that ranged from 4.0% to 4.5%. The estimated useful life of the technology is based upon management’s estimate of the product life cycle associated with the technology before they will be replaced by new technologies. (2.) BUSINESS ACQUISITIONS (Continued) Tradenames - Tradenames represents the estimated fair value of Oscor’s corporate and product names. The acquired tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a royalty rate of 2.0%. Tradenames were assumed to have a definite useful life based upon long-term management expectations and future operating plans. 2020 Acquisition On February 19, 2020, the Company acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enabled the Company to create a research and development center in Israel, closer to the customer base in the region. The fair value of the consideration transferred was $7.0 million, which included an initial cash payment of $5.3 million and $1.7 million in estimated fair value of contingent consideration. The contingent consideration represented the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $3.5 million if specified conditions are met through February 2024. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. Based on the final purchase price allocation, the assets acquired principally comprise $2.0 million of intangible assets, $4.8 million of goodwill, $0.3 million of acquired property, plant and equipment, and a net liability for other working capital items of $0.1 million. Intangible assets included developed technology, customer relationships and non-compete provisions, which are being amortized over a weighted average period of 5.9 years. Goodwill for the InoMec acquisition is deductible for income tax purposes. 2019 Acquisition On October 7, 2019, the Company acquired certain assets and liabilities of US BioDesign, LLC (“USB”), a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition added a differentiated capability related to the complex development and manufacture of braided and formed biomedical structures to the Company’s broad portfolio. The fair value of the consideration transferred was $19.1 million, which included a cash payment of $14.9 million and $4.2 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $5.5 million if certain revenue goals are met through 2023. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. Based on the final purchase price allocation, the assets acquired principally consist of $7.4 million of developed technology, $10.4 million of goodwill, $0.7 million of acquired property, plant and equipment, and $0.6 million of other working capital items. The $10.4 million of goodwill reflects a $0.1 million decrease resulting from a favorable working capital adjustment recorded in 2020. The technology intangible asset is being amortized over a useful life of 8 years. Goodwill for the USB acquisition is deductible for income tax purposes. Actual and Pro Forma (unaudited) disclosures For segment reporting purposes, the results of operations and assets from the Oscor, InoMec and USB acquisitions have been included in the Company’s Medical segment since the respective acquisition dates. For the year ended December 31, 2021, sales related to Oscor, InoMec and USB were $4.7 million, $3.5 million and $4.8 million, respectively. For the year ended December 31, 2020, sales related to InoMec and USB were $3.4 million and $4.5 million, respectively. For the year ended December 31, 2019, sales related to USB were $0.8 million. Earnings related to the operations of Oscor, InoMec and USB for the fiscal years 2021, 2020 and 2019 were not material. Pro forma financial information has not been presented for the InoMec and USB acquisitions as the net effects were not significant or material to the Company’s results of operations or financial position. (2.) BUSINESS ACQUISITIONS (Continued) The following unaudited pro forma information presents the consolidated results of operations of the Company and Oscor as if the acquisition occurred as of the beginning of fiscal year 2020 (in thousands): 2021 2020 Sales $ 1,274,148 $ 1,128,137 Income from continuing operations $ 91,844 $ 67,529 The unaudited pro forma results are presented for illustrative purposes only and do not reflect the realization of potential cost savings, and any related integration costs. Certain costs savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These unaudited pro forma results do not purport to be indicative of the results that would have been obtained, or to be a projection of results that may be obtained in the future. These unaudited pro forma results include certain adjustments, primarily due to increases in amortization expense due to the fair value adjustments of intangible assets, the increases to interest expense reflecting the amount borrowed in connection with the acquisition, acquisition related costs and the impact of income taxes on the pro forma adjustments. Acquisition costs During the fiscal years 2021, 2020 and 2019, direct costs of these acquisitions of $2.0 million, $0.9 million and $0.4 million, respectively, were expensed as incurred and included in Other Operating Expenses in the Consolidated Statements of Operations.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION The following represents supplemental cash flow information for fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Non-cash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 5,556 $ 3,597 $ 8,646 Cash paid during the year for: Interest 24,740 33,933 44,784 Income taxes 19,649 18,477 30,034

Inventories

Inventories	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories comprise the following (in thousands): December 31, December 31, Raw materials $ 70,956 $ 72,477 Work-in-process 74,152 58,806 Finished goods 10,591 18,040 Total $ 155,699 $ 149,323

Property, Plant and Equipment,

Property, Plant and Equipment, Net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET PP&E comprises the following (in thousands): December 31, 2021 December 31, Manufacturing machinery and equipment $ 352,391 $ 320,807 Buildings and building improvements 98,007 102,037 Information technology hardware and software 72,752 69,969 Leasehold improvements 85,931 77,382 Furniture and fixtures 17,099 16,250 Land and land improvements 13,980 11,598 Construction work in process 41,813 26,389 Other 1,431 1,238 683,404 625,670 Accumulated depreciation (406,305) (371,706) Total $ 277,099 $ 253,964 Depreciation expense for PP&E was as follows for fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Depreciation expense $ 39,772 $ 38,193 $ 37,819

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS, NET	GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The change in the carrying amount of goodwill by reportable segment during fiscal years 2021 and 2020 was as follows (in thousands): Medical Non-Medical Total December 31, 2019 $ 822,617 $ 17,000 $ 839,617 Acquisition 4,800 — 4,800 Acquisition-related adjustments (Note 2) (85) — (85) Foreign currency translation 15,110 — 15,110 December 31, 2020 842,442 17,000 859,442 Acquisition (Note 2) 77,887 — 77,887 Foreign currency translation (12,625) — (12,625) December 31, 2021 $ 907,704 $ 17,000 $ 924,704 As of December 31, 2021, no accumulated impairment loss has been recognized for the goodwill allocated to the Company’s Medical or Non-Medical segments. (6. ) GOODWILL AND OTHER INTANGIBLE ASSETS, NET (Continued) Intangible Assets Intangible assets comprise the following (in thousands): Gross Accumulated Net December 31, 2021 Definite-lived: Purchased technology, tradenames and patents $ 285,659 $ (164,371) $ 121,288 Customer lists 783,618 (187,412) 596,206 Other 4,162 (4,134) 28 Total amortizing intangible assets $ 1,073,439 $ (355,917) $ 717,522 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2020 Definite-lived: Purchased technology and patents $ 257,453 $ (152,798) $ 104,655 Customer lists 723,791 (161,856) 561,935 Other 4,142 (3,796) 346 Total amortizing intangible assets $ 985,386 $ (318,450) $ 666,936 Indefinite-lived: Trademarks and tradenames $ 90,288 See Note 2 “Business Acquisitions” for additional details regarding intangible assets acquired during 2021 and 2020. Included in the Company’s indefinite-lived intangible assets are the Lake Region Medical and Greatbatch Medical tradenames with carrying values of $70.0 million and $20.3 million, respectively. When acquiring certain assets, the Company assesses whether the acquired assets are a result of a business combination or a purchase of an asset. During 2020, the Company acquired a set of similar identifiable intangible assets relating to a license to use technology within its Non-Medical segment. The Company purchased the technology for $4.5 million, which includes $1.0 million of contingent consideration paid during 2020 upon completion of certain milestones, and capitalized $0.1 million of costs associated with acquiring the license as an intangible asset. The intangible asset of $4.6 million is being amortized over 11 years, the remaining useful life of the patented technology. Aggregate intangible asset amortization expense comprises the following for fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Cost of sales $ 13,090 $ 12,860 $ 13,111 SG&A 28,507 28,271 26,965 Total intangible asset amortization expense $ 41,597 $ 41,131 $ 40,076 Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2021 is as follows (in thousands): 2022 2023 2024 2025 2026 After 2026 Amortization expense $ 46,594 $ 48,490 $ 47,576 $ 45,946 $ 43,612 $ 485,304

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2021
Accounts Payable and Accrued Liabilities [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities comprise the following (in thousands): December 31, 2021 December 31, Salaries and benefits $ 27,733 $ 24,512 Profit sharing and bonuses 18,325 19,204 Contract liabilities 3,776 2,498 Product warranties 509 163 Accrued interest 76 1,644 Other 6,514 8,822 Total $ 56,933 $ 56,843

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
DEBT	DEBT Long-term debt comprises the following (in thousands): December 31, 2021 December 31, Senior secured term loan A $ 467,062 $ 229,687 Senior secured term loan B 349,125 508,286 Senior secured revolving credit facility 19,300 — Unamortized discount on term loan B and deferred debt issuance costs (7,361) (6,715) Total debt 828,126 731,258 Current portion of long-term debt (15,250) (37,500) Total long-term debt $ 812,876 $ 693,758 Senior Secured Credit Facilities On September 2, 2021, the Company entered into a new credit agreement (the “2021 Credit Agreement”), which permits borrowings and other extensions of credit in an initial aggregate principal amount of up to $1 billion (as may be increased from time to time in accordance with the terms). The 2021 Credit Agreement governs the Company’s senior secured credit facilities (the “Senior Secured Credit Facilities”), which consist of a five-year $400 million revolving credit facility (the “Revolving Credit Facility”), a five-year $250 million “term A” loan (the “TLA Facility”) and a seven-year $350 million “term B” loan (the “TLB Facility” and, together with the TLA Facility, the “Term Loan Facilities”). The TLB Facility was issued at a 0.50% discount. The 2021 Credit Agreement also includes an alternative benchmark rate as a replacement to the London Interbank Offered Rate (“LIBOR”) in the event LIBOR is no longer available. In connection with closing of the Oscor acquisition, on December 1, 2021, the Company amended the 2021 Credit Agreement to provide for, among other things, the incurrence of an additional $220 million aggregate principal amount of term A loans. As of December 31, 2021, the weighted average interest rate on all outstanding borrowings is 2.04%. The obligations under the 2021 Credit Agreement are guaranteed by certain specified subsidiaries of the Company. Among other things, the 2021 Credit Agreement contains covenants that restrict the Company’s and certain of its subsidiaries’ ability to incur liens on certain assets, incur indebtedness, make material changes in corporate structure or materially alter the nature of its business, dispose of material assets, engage in mergers, consolidations and certain other fundamental changes, or engage in certain transactions with affiliates. The 2021 Credit Agreement contains customary default provisions, including, but not limited to, failure to pay interest or principal when due and failure to comply with covenants. (8.) DEBT (Continued) Prior to September 2, 2021, the Company was party to an amended and restated credit agreement (the “2015 Credit Agreement”), dated as of October 27, 2015. The 2015 Credit Agreement provided for certain credit facilities to the Company in an aggregate principal amount not to initially exceed $1.6 billion. At the time of the refinancing on September 2, 2021, the 2015 Credit Agreement provided for a $200 million revolving credit facility with no outstanding borrowings, a term loan A facility and a term loan B facility with outstanding principal balances of $210.9 million and $462.3 million, respectively. The term loan B facility under the 2015 Credit Agreement was issued at a 1% discount. The 2015 Credit Agreement was terminated concurrently with entering into the 2021 Credit Agreement. Details of our Long-term debt as of December 31, 2020 can be found within our 2020 Form 10-K . Revolving Credit Facility The Revolving Credit Facility matures on September 2, 2026 and includes a $40 million sublimit for swingline loans and standby letters of credit. As of December 31, 2021, the Company had available borrowing capacity on the Revolving Credit Facility of $375.0 million after giving effect to $19.3 million of outstanding borrowings and $5.7 million of outstanding standby letters of credit. Interest rates on the Revolving Credit Facility are at the Company’s option, either at: (i) the applicable LIBOR (or an applicable benchmark replacement) plus the applicable margin, which will range between 1.25% and 2.25%, based on the Company’s Total Net Leverage Ratio (as defined in the 2021 Credit Agreement), or (ii) the Base Rate (as defined below) plus the applicable margin, which will range between 0.25% and 1.25%, based on the Company’s Total Net Leverage Ratio. The Base Rate is defined, for any day, as the per annum rate equal to the highest of (i) the prime rate (as defined in the 2021 Credit Agreement), (ii) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 0.50%, and (iii) one-month LIBOR plus 1.00%. As of December 31, 2021, the weighted average interest rate on outstanding borrowings under the Revolving Credit Facility was 1.35%. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.15% and 0.25%, depending on the Company’s Total Net Leverage Ratio. As of December 31, 2021, the commitment fee on the unused portion of the Revolving Credit Facility was 0.15%. Term Loan Facilities The TLA Facility and TLB Facility mature on September 2, 2026 and September 2, 2028, respectively, and require quarterly principal installments. The quarterly principal installments under the TLA Facility increase over the term of the loan. The interest rate terms for the TLA Facility are the same as those outlined above for the Revolving Credit Facility. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the applicable LIBOR rate plus 2.50%, with LIBOR subject to a 0.50% floor, or (ii) the Base Rate plus 1.50%. As of December 31, 2021, the interest rates on the TLA Facility and TLB Facility were 1.35% and 3.00%, respectively. Covenants The 2021 Credit Agreement contains customary terms and conditions, including representations and warranties and affirmative and negative covenants, as well as financial covenants for the benefit of the lenders under the Revolving Credit Facility and the TLA Facility, which require that (i) the Company maintain a Total Net Leverage Ratio not to exceed 5.50:1.00 (stepping down to 5.00:1.00 for the third fiscal quarter of 2023 through maturity and subject to increase in certain circumstances following qualified acquisitions, but shall not exceed 5.50:1.00) and (ii) the Company maintain an interest coverage ratio of at least 2.50:1.00. The TLB Facility does not contain any financial maintenance covenants. As of December 31, 2021, the Company was in compliance with these financial covenants. Contractual maturities under the Senior Secured Credit Facilities for the next five years and thereafter, as of December 31, 2021, are as follows (in thousands): 2022 2023 2024 2025 2026 After 2026 Future minimum principal payments $ 15,250 $ 18,188 $ 29,938 $ 38,750 $ 401,739 $ 331,622 (8.) DEBT (Continued) Deferred Debt Issuance Costs and Discounts The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands): December 31, 2020 891 Financing costs incurred 2,762 Write-off of deferred debt issuance costs (72) Amortization during the period (542) December 31, 2021 $ 3,039 The change in unamortized discount and deferred debt issuance costs related to the Term Loan Facilities is as follows (in thousands): Deferred Debt Issuance Costs Unamortized Discount on TLB Facility Total December 31, 2020 5,258 1,457 6,715 Financing costs incurred 5,236 1,750 6,986 Write-off of deferred debt issuance costs and unamortized discount (2,677) (954) (3,631) Amortization during the period (2,143) (566) (2,709) December 31, 2021 $ 5,674 $ 1,687 $ 7,361 In connection with the 2021 Credit Agreement, the Company incurred and capitalized $8.8 million of issuance costs, including an original issue discount on the TLB Facility of $1.8 million. In connection with December 1, 2021 amendment to the TLA Facility, the Company incurred and capitalized $1.0 million of issuance costs. An aggregate of $7.0 million of original issue discount and debt issuance costs have been recorded as a reduction of the carrying value of the related debt and $2.8 million of debt issuance costs attributable to the Revolving Credit Facility have been recorded as a component of Other long-term assets on the Consolidated Balance Sheets as of December 31, 2021. In connection with terminating the 2015 Credit Agreement and entering into the 2021 Credit Agreement, for each separate debt instrument on a lender by lender basis, in accordance with ASC 470-50, Debt Modifications and Extinguishment , the Company performed an assessment of whether the transaction was deemed to be new debt, a modification of existing debt, or an extinguishment of existing debt. Debt issuance costs are either deferred and amortized over the term of the associated debt or expensed as incurred. Based on this assessment, $1.2 million of unamortized deferred debt issuance costs and unamortized discount related to the 2015 Credit Agreement were deemed to be related to the issuance of new debt, or the modification of existing debt, and therefore will continue to be deferred and amortized over the term of the associated debt. The remaining $3.3 million of unamortized deferred debt issuance costs and unamortized discount related to the 2015 Credit Agreement were deemed to be related to the extinguishment of debt and were expensed. Additionally, in connection with prepayments on the TLB Facility made during 2021 under the 2015 Credit Agreement, $0.3 million of unamortized deferred debt issuance costs and unamortized discount were treated as extinguishment of debt and were expensed.

Benefit Plans

Benefit Plans	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
BENEFIT PLANS	BENEFIT PLANS Savings Plan The Company sponsors a defined contribution 401(k) plan (the “Plan”) for its U.S. based employees. The Plan provides for the deferral of employee compensation under Internal Revenue Code §401(k) and a Company match. The Company matches $0.50 per dollar of each participant’s deferral made to the Plan up to 6% of their compensation, subject to Internal Revenue Service guidelines. The Company temporarily suspended the Company match beginning in August 2020 through the end of 2020 as part of its cost reduction actions to reduce discretionary spending in response to the effect of the COVID-19 pandemic on its operations. Contributions from employees, as well as those matched by the Company, vest immediately. Net costs related to defined contribution plans were $7.9 million in 2021, $5.0 million in 2020 and $7.2 million in 2019. Defined Benefit Plans The Company is required to provide its employees located in Switzerland and Mexico certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico are unfunded and noncontributory. The assets of the Switzerland plan are held at an AA- rated insurance carrier who bears the pension risk and longevity risk, and will be used to cover the pension liability for the remaining retirees of the Swiss plan, as well as the remaining employees at that location. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The aggregated projected benefit obligation for these plans was $3.9 million and $3.7 million as of December 31, 2021 and December 31, 2020, respectively. Net periodic pension cost for fiscal years 2021, 2020 and 2019 was $0.5 million, $0.4 million and $0.3 million, respectively. Over the next ten years, we expect gross benefit payments to be $1.0 million in total for the years 2022 through 2026, and $1.8 million in total for the years 2027 through 2031.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Stock-based Compensation Plans The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors (the “Board”) or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, RSAs, RSUs, stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers. On March 25, 2021, the Company’s Board adopted, subject to stockholder approval, the Integer Holdings Corporation 2021 Omnibus Incentive Plan (the “2021 Plan”). The Company’s stockholders approved the 2021 Plan at the Company’s 2021 annual meeting of stockholders on May 19, 2021, at which time the 2021 Plan replaced the Company’s 2016 Stock Incentive Plan (the “2016 Plan”) and the Company ceased granting any new awards under the 2016 Plan. The number of shares initially reserved for issuance under the 2021 Plan is (i) 1,450,000 plus (ii) the total number of shares of common stock available for issuance under the 2016 Plan, plus (iii) any shares of common stock that are subject to awards forfeited, cancelled, expired, terminated or otherwise lapsed or settled in cash, in whole or in part, without the delivery of shares under the 2016 Plan. Each of the Company’s 2011 Stock Incentive Plan, the 2009 Stock Incentive Plan and the 2005 Stock Incentive Plan have expired, and no awards are available for issuance under these expired plans. As of December 31, 2021, there were 1,636,980 shares available for future grants under the 2021 Plan. The Company recognized an excess net tax benefit from the exercise of stock options and vesting of RSUs of $1.1 million, $1.5 million and $2.8 million for fiscal years 2021, 2020 and 2019, respectively. These amounts are recorded as a component of Provision for income taxes. (10.) STOCK-BASED COMPENSATION (Continued) Stock-based Compensation Expense The components and classification of stock-based compensation expense for fiscal years 2021, 2020 and 2019 were as follows (in thousands): 2021 2020 2019 Stock options $ — $ 43 $ 410 RSUs and PRSUs 16,185 9,120 8,884 Total stock-based compensation expense $ 16,185 $ 9,163 $ 9,294 Cost of sales $ 3,365 $ 1,658 $ 1,011 SG&A 11,579 6,942 7,827 RD&E 969 563 269 OOE 272 — 187 Total stock-based compensation expense $ 16,185 $ 9,163 $ 9,294 Stock Options There were no stock options granted in fiscal years 2021, 2020 or 2019. The following table summarizes stock option activity during the fiscal year ended December 31, 2021: Number of Weighted Weighted Aggregate Outstanding at December 31, 2020 281,873 $ 36.05 Exercised (34,233) 21.72 Outstanding at December 31, 2021 247,640 $ 38.03 4.2 $ 11.8 Vested and exercisable at December 31, 2021 247,640 $ 38.03 4.2 $ 11.8 Intrinsic value is calculated for in-the-money options (exercise price less than market price) as the difference between the market price of the Company’s common stock as of December 31, 2021 ($85.59) and the weighted average exercise price of the underlying stock options, multiplied by the number of options outstanding and/or exercisable. Shares are distributed from the Company’s authorized but unissued reserve upon the exercise of stock options. The following table provides certain information relating to the exercise of stock options during fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Intrinsic value $ 2,370 $ 4,773 $ 7,998 Cash received 743 3,263 3,242 Restricted Stock Units The following table summarizes RSU activity during the fiscal year ended December 31, 2021: Time-Vested Weighted Nonvested at December 31, 2020 207,923 $ 75.38 Granted 208,624 81.98 Vested (149,464) 74.47 Forfeited (18,952) 79.84 Nonvested at December 31, 2021 248,131 $ 81.14 (10.) STOCK-BASED COMPENSATION (Continued) As of December 31, 2021, there was $13.9 million of total unrecognized compensation cost related to RSUs, which is expected to be recognized over a weighted-average period of approximately 1.6 years. The fair value of RSU shares vested in fiscal years 2021, 2020 and 2019 was $12.9 million, $9.9 million and $2.4 million, respectively. The weighted average grant date fair value of RSUs granted during fiscal years 2021, 2020 and 2019 was $81.98, $83.94 and $82.31, respectively. Performance Restricted Stock Units The following table summarizes PRSU activity during the fiscal year ended December 31, 2021: Performance- Weighted Nonvested at December 31, 2020 219,391 $ 72.33 Granted 92,384 85.16 Vested (38,882) 37.75 Forfeited (74,024) 53.45 Nonvested at December 31, 2021 198,869 $ 92.07 For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares earned depends on the achievement of financial or market-based performance conditions. The financial performance condition is based on the Company’s sales targets. The market conditions are based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over three year performance periods. All PRSUs awarded during the 2021 fiscal year were subject to market-based performance conditions. At December 31, 2021, there was $6.0 million of total unrecognized compensation cost related to unvested PRSUs, which is expected to be recognized over a weighted-average period of approximately 1.9 years. The fair value of PRSU shares vested in fiscal years 2021, 2020 and 2019 was $3.1 million, $2.9 million and $6.7 million, respectively. The weighted average grant date fair value of PRSUs granted during fiscal years 2021, 2020 and 2019 was $85.16, $95.06 and $101.17, respectively. The grant-date fair value of the market-based portion of the PRSUs granted during fiscal years 2021, 2020 and 2019 was determined using the Monte Carlo valuation model on the date of grant. The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows: 2021 2020 2019 Weighted average fair value $ 85.16 $ 107.27 $ 117.03 Risk-free interest rate 0.19 % 1.29 % 2.46 % Expected volatility 41 % 30 % 40 % Expected life (in years) 3.0 2.9 2.8 Expected dividend yield — % — % — % The valuation of the TSR portion of the PRSUs granted during fiscal years 2021 and 2020 also reflects a weighted average illiquidity discount of 8.19% and 8.00%, respectively, related to the six-month period that recipients are restricted from selling, transferring, pledging or assigning the underlying shares, in the event of vesting.

Other Operating Expenses

Other Operating Expenses	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
OTHER OPERATING EXPENSES	OTHER OPERATING EXPENSES The Company continuously evaluates the business and identifies opportunities to realign its resources to better serve its customers and markets, improve operational efficiency and capabilities, and lower its operating costs. To realize the benefits associated with these opportunities, the Company undertakes restructuring-type activities to transform its business. In addition, from time to time, the Company incurs cost associated with acquiring and integrating businesses and certain other general expenses, including asset impairments. The Company classifies costs associated with these items as OOE. The following tables summarize OOE by program in each of the preceding three years (in thousands): 2021 2020 2019 Operational excellence initiatives $ 3,893 $ 2,791 $ — Strategic reorganization and alignment 911 686 5,812 Manufacturing alignment to support growth — 241 2,145 Acquisition and integration costs (adjustments) 2,544 (776) 377 Other general expenses 508 4,679 3,817 Total other operating expenses $ 7,856 $ 7,621 $ 12,151 Operational excellence initiatives The Company’s operational excellence (“OE”) initiatives mainly consist of costs associated with executing on its sales force, manufacturing, business process, and performance excellence operational strategic imperatives. These projects focus on changing the Company’s organizational structure to match product line growth strategies and customer needs, transitioning its manufacturing process into a competitive advantage and standardizing and optimizing its business processes. 2021 OE Initiatives - Costs related to the Company’s 2021 OE initiatives are primarily recorded within the Medical segment or unallocated operating expenses and mainly include termination benefits. The Company estimates that it will incur aggregate pre-tax charges in connection with the 2021 OE initiatives of between approximately $4 million to $5 million, the majority of which are expected to be cash expenditures. As of December 31, 2021, total restructuring and related charges incurred since inception were $3.6 million. These actions are expected to be substantially complete by the end of 2022. 2020 Initiatives - Costs related to the Company’s 2020 initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2021, total restructuring and related charges incurred since inception were $3.1 million. These actions were substantially complete at the end of 2020. Strategic reorganization and alignment The Company’s strategic reorganization and alignment (“SRA”) initiatives primarily include those that align resources with market conditions and the Company’s strategic direction in order to enhance the profitability of its portfolio of products. 2021 SRA Initiatives - During the fourth quarter of 2021, the Company initiated plans to exit certain markets served in our Medical segment to enhance profitability and reallocate manufacturing capacity needed to support our overall growth plans. The Company estimates that it will incur a range of pre-tax charges in connection with the 2021 SRA initiatives of approximately $5 million and $8 million, the majority of which are expected to be cash expenditures. Costs related to the Company’s 2021 SRA Initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of December 31, 2021, total charges incurred since inception were $0.9 million. These actions are expected to be completed by the end of 2025. 2017 SRA Initiatives - In 2017, to better align its resources to enhance the profitability of its portfolio of products, the Company began aligning resources with its strategic direction, improving profitability to invest in accelerated growth and the expansion of a facility. These actions began in 2017 and were completed during the second quarter of 2020. The Company recorded, primarily within the Medical segment, $23.0 million of restructuring and related charges since inception. (11.) OTHER OPERATING EXPENSES (Continued) Manufacturing alignment to support growth In 2017, the Company commenced several initiatives designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies. The plan involved the relocation of certain manufacturing operations and expansion of certain of the Company’s facilities. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical segment. As of December 31, 2021, total restructuring and related charges incurred for this initiative since inception were $5.8 million. These actions were completed during 2020. The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Consolidated Balance Sheets, related to the initiatives described above (in thousands): Operational excellence initiatives Strategic reorganization and alignment Total December 31, 2020 $ 291 $ — $ 291 Charges incurred, net of reversals 3,893 911 4,804 Cash payments (3,886) (777) (4,663) December 31, 2021 $ 298 $ 134 $ 432 Acquisition and integration costs During 2021, acquisition and integration costs included $2.4 million of expenses primarily related to the acquisition of Oscor, and a net $0.1 million adjustment to increase the fair value of acquisition-related contingent consideration liability associated with the Company’s other acquisitions. During 2020, acquisition and integration costs included $1.2 million of expenses primarily related to the acquisition of certain assets and liabilities of InoMec, and a $2.0 million adjustment to reduce the fair value of acquisition-related contingent consideration liability associated with the Company’s acquisition of USB. During 2019, acquisition and integration costs primarily related to direct acquisition costs incurred in connection with the acquisition of USB. Acquisition and integration costs primarily consist of professional fees and other costs. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. Other general expenses During 2021, 2020 and 2019, the Company recorded expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies. The 2021, 2020 and 2019 amounts primarily include severance, information technology systems conversion expenses, expenses incurred in connection with a customer filing Chapter 11 bankruptcy, and expenses related to the restructuring of certain legal entities of the Company.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income from continuing operations before taxes for fiscal years 2021, 2020 and 2019 consisted of the following (in thousands): 2021 2020 2019 U.S. $ 48,293 $ 35,337 $ 40,203 International 52,770 50,870 64,990 Total income from continuing operations before taxes $ 101,063 $ 86,207 $ 105,193 The provision for income taxes from continuing operations for fiscal years 2021, 2020 and 2019 comprises the following (in thousands): 2021 2020 2019 Current: Federal $ 9,511 $ 7,784 $ 14,090 State 1,553 1,233 87 International 8,459 6,898 10,083 19,523 15,915 24,260 Deferred: Federal (8,665) (4,648) (8,813) State (393) (1,245) 332 International (2,422) (1,073) (1,804) (11,480) (6,966) (10,285) Total provision for income taxes $ 8,043 $ 8,949 $ 13,975 The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2021, 2020 and 2019 due to the following: 2021 2020 2019 Statutory rate $ 21,223 21.0 % $ 18,103 21.0 % $ 22,091 21.0 % Federal tax credits (including R&D) (11,929) (11.8) (7,009) (8.1) (4,797) (4.6) Foreign rate differential (5,165) (5.1) (5,333) (6.2) (5,479) (5.2) Stock-based compensation (1,084) (1.1) (1,459) (1.7) (2,422) (2.3) Uncertain tax positions 18 — 1,208 1.4 (920) (0.9) State taxes, net of federal benefit 1,183 1.2 553 0.6 1,106 1.1 U.S. tax on foreign earnings, net of §250 deduction 1,913 1.9 3,216 3.7 5,201 4.9 Valuation allowance 524 0.5 (345) (0.4) (1,606) (1.5) Other 1,360 1.4 15 0.1 801 0.8 Effective tax rate $ 8,043 8.0 % $ 8,949 10.4 % $ 13,975 13.3 % The difference between the Company’s effective tax rate and the U.S. federal statutory income tax rate in the current year is primarily attributable to the availability of Foreign Tax Credits, R&D Credits, the impact of the Company’s earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate, and the provision for Global Intangible Low Taxed income (“GILTI”), net of the statutory deduction of 50% of the GILTI inclusion and the Foreign Derived Intangible Income (“FDII”) deduction (collectively “Section 250 deduction”). The Company’s foreign earnings are primarily derived from Switzerland, Mexico, Uruguay, Ireland and Malaysia. The Company currently has a tax holiday in Malaysia through April 2023 provided certain conditions continue to be met. In addition, the Company acquired manufacturing operations in the Dominican Republic as part of the acquisition of Oscor and is operating under a free trade zone agreement in the Dominican Republic through March 2034. (12.) INCOME TAXES (Continued) Difference Attributable to Foreign Investment: Certain foreign subsidiary earnings are subject to U.S. taxation under the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) . The Company intends to permanently reinvest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, with the exception of planned distributions made out of current year earnings and profits (“E&P”) and E&P previously taxed as of and for the year ended December 29, 2017, including E&P subject to the toll charge under the Tax Reform Act. The Company accrues for withholding taxes on distributions in the year associated with earnings that are intended to be distributed. The net deferred tax liability consists of the following (in thousands): December 31, December 31, Tax credit carryforwards $ 11,394 $ 13,449 Inventories 14,147 14,099 Net operating loss carryforwards 11,721 10,436 Operating lease liabilities 17,950 11,969 Stock-based compensation 3,724 3,276 Accrued expenses 9,348 8,058 Gross deferred tax assets 68,284 61,287 Less valuation allowance (19,456) (20,739) Net deferred tax assets 48,828 40,548 Property, plant and equipment (7,354) (5,824) Intangible assets (186,150) (197,048) Operating lease assets (17,974) (11,290) Other (3,144) (4,292) Gross deferred tax liabilities (214,622) (218,454) Net deferred tax liability $ (165,794) $ (177,906) Presented as follows: Noncurrent deferred tax asset $ 5,711 $ 4,398 Noncurrent deferred tax liability (171,505) (182,304) Net deferred tax liability $ (165,794) $ (177,906) As of December 31, 2021, the Company has the following carryforwards available: Jurisdiction Tax Amount Begin to Expire U.S. State Net operating losses (1) $ 120.7 2022 International Net operating losses (1) 12.2 2022 U.S. Federal Foreign tax credits 6.7 2022 U.S. State R&D tax credits 1.4 2022 U.S. State State tax credits 4.9 2022 __________ (1) Net operating losses (“NOLs”) are presented as pre-tax amounts. (12.) INCOME TAXES (Continued) In assessing the realizability of deferred tax assets, management considers, within each taxing jurisdiction, whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on the consideration of the weight of both positive and negative evidence, management has determined it is more likely than not that a portion of the deferred tax assets as of December 31, 2021 and December 31, 2020 related to certain foreign tax credits, state investment tax credits, and foreign and state net operating losses will not be realized. The Company files annual income tax returns in the U.S., various state and local jurisdictions, and in various foreign jurisdictions. A number of years may elapse before an uncertain tax position, for which the Company has unrecognized tax benefits, is examined and finally settled. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its unrecognized tax benefits reflect the most probable outcome. The Company adjusts these unrecognized tax benefits, as well as the related interest, in light of changing facts and circumstances. The resolution of an uncertain tax position, if recognized, would be recorded as an adjustment to the provision for income taxes and the effective tax rate in the period of resolution. Below is a summary of changes to the unrecognized tax benefit for fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Balance, beginning of year $ 5,484 $ 4,446 $ 5,369 Additions based upon tax positions related to the current year 3,324 300 300 Additions (reductions) related to prior period tax returns (3,271) 738 (1,223) Balance, end of year $ 5,537 $ 5,484 $ 4,446 The tax years that remain open and subject to tax audits vary depending on the tax jurisdiction. During 2021, the Internal Revenue Service (“IRS”) effectively concluded its examination of the U.S. subsidiaries of the Company for the taxable years 2017 and 2018. Taxable years 2019 and forward remain subject to examination by the IRS. The balance of unrecognized tax benefits is not expected to materially change over the course of the next twelve months as a result of the lapse of the statute of limitations and/or audit settlements. As of December 31, 2021, approximately $5.5 million of unrecognized tax benefits would favorably impact the effective tax rate (net of federal impact on state issues), if recognized. The Company recognizes interest related to unrecognized tax benefits as a component of Provision for income taxes on the Consolidated Statements of Operations. During 2021, 2020 and 2019, the recorded amounts for interest and penalties, respectively, were not significant. In response to the COVID-19 pandemic, many governments have enacted or are contemplating measures to provide aid and economic stimulus. These measures may include deferring the due dates of tax payments or other changes to their income and non-income-based tax laws. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020 in the U.S., includes measures to assist companies, including temporary changes to income and non-income-based tax laws. The CARES Act provided for deferred payment of the employer portion of social security taxes through the end of 2020. As of December 31, 2020, the Company had deferred a total of $9.7 million of payroll taxes, of which it paid $4.9 million in December 2021. As of December 31, 2021, the Company had a remaining deferred amount of $4.8 million, which the Company expects to pay withing the next twelve months. The deferred payroll taxes are included within Accrued expenses and other current liabilities on the Consolidated Balance Sheets. See Note 20 “Discontinued Operations” for additional information pertaining to income taxes from discontinued operations.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Contingent Consideration Arrangements The Company records contingent consideration liabilities related to the earn-out provisions for certain acquisitions. See Note 17 “Financial Instruments and Fair Value Measurements” for additional information. Litigation The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action will not become material in the future. The Company records a contingent gain for litigation when all of the following conditions have been met: (a) the amount to be paid to the Company is known, (b) there is no potential for appeal or reversal, and (c) collectability is reasonably assured. In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. Following four trials and an appeal, the United States Court of Appeals for the Federal Circuit affirmed, in all respects, a judgment in favor of the Company. The Company received the payment of $28.9 million in October 2020, and after recognizing certain related expenses, recognized a net gain of $28.2 million. Selling, general and administrative expenses The net gain on patent litigation of $28.2 million is recorded in Selling, g eneral and administrative expenses in the Company’s Consolidated Statements of Operations for the year ended December 31, 2020. Environmental Matters The Company acquired Lake Region Medical Holdings, Inc. (“LRM”) in 2015. At the direction of the New Jersey Department of Environmental Protection (“NJDEP”), LRM has been performing, and has agreed to fund approximately $0.3 million for, environmental investigations of a manufacturing facility LRM owned in South Plainfield, New Jersey from 1971 to 2004, and where it conducted operations from 1971 to 2007. NJDEP required LRM to perform and fund these environmental investigations due to concerns that prior investigations by LRM at the property were inadequate and because NJDEP concluded that the property was a source of local ground water contamination during LRM’s operations, including the Franklin Street Regional Groundwater Contamination Area, which has been designated as an immediate environmental concern by NJDEP. LRM funded the environmental investigation undertaken by NJDEP’s contractor by placing approximately $0.3 million in escrow for the environmental investigation. As of December 31, 2021, approximately $0.2 million had been drawn down from the escrow account by NJDEP to pay for the environmental investigation, and approximately $0.1 million remains in escrow for anticipated future costs associated with the environmental investigation. These environmental investigations may conclude that remediation of the property by LRM, and the reimbursement of costs and damages, including natural resource damages, associated with the groundwater immediate environmental concern, are necessary. Further, the current owner of the property claims to have been financially impacted by LRM’s inadequate environmental investigations. While the Company does not expect this environmental matter will have a material effect on its consolidated results of operations, financial position or cash flows, there can be no assurance that this environmental matter will not become material in the future. As of December 31, 2021, there was $0.1 million recorded in Accrued expenses and other current liabilities in the Consolidated Balance Sheets in connection with this environmental matter . License Agreements The Company is a party to various license agreements for technology that is utilized in certain of its products. The most significant of these agreements are the licenses for basic technology used in the production of wet tantalum capacitors, filtered feedthroughs and MRI compatible lead systems. Expenses related to license agreements were $1.3 million, $1.2 million, and $1.4 million, for 2021, 2020 and 2019, respectively, and are primarily included in Cost of Sales. (13.) COMMITMENTS AND CONTINGENCIES (Continued) Product Warranties The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in product warranty liability for fiscal years 2021 and 2020 comprises the following (in thousands): 2021 2020 Beginning balance $ 163 $ 1,933 Additions to warranty reserve, net of reversals (15) (156) Adjustments to pre-existing warranties (71) (119) Warranty claims settled — (1,495) Acquisitions $ 432 — Ending balance $ 509 $ 163 Self-Insurance Liabilities

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	LEASES The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Gross assets acquired under finance leases are recorded in Other long-term assets and were $8.3 million as of December 31, 2021. Accumulated amortization associated with finance leases was $0.2 million as of December 31, 2021. Finance leases were not material as of December 31, 2020. The components and classification of lease cost are as follows (in thousands): December 31, December 31, Finance lease cost: Amortization of lease assets $ 223 $ 7 Interest on lease liabilities 59 1 Finance lease cost 282 8 Operating lease cost 10,729 10,425 Short-term lease cost (leases with initial term of 12 months or less) 137 86 Variable lease cost 2,619 2,615 Sublease income (1,392) (1,495) Total lease cost $ 12,375 $ 11,639 Cost of sales $ 9,642 $ 9,141 SG&A 1,817 1,803 RD&E 857 694 Interest expense $ 59 $ 1 Total lease cost $ 12,375 $ 11,639 (14.) LEASES (Continued) The Company’s sublease income is derived primarily from certain real estate leases to several non-affiliated tenants under operating sublease arrangements. At December 31, 2021, the maturities of operating and finance lease liabilities were as follows (in thousands): Operating Leases Finance Leases 2022 $ 12,423 $ 876 2023 11,317 888 2024 10,809 896 2025 10,634 787 2026 9,856 640 Thereafter 25,652 5,807 Gross lease liabilities 80,691 9,894 Less: imputed interest (11,062) (1,836) Present value of lease liabilities 69,629 8,058 Less: current portion of lease liabilities (9,862) (608) Total long-term lease liabilities $ 59,767 $ 7,450 As of December 31, 2021, the Company did not have any leases that have not yet commenced. The following table presents the weighted average remaining lease term and discount rate. December 31, December 31, Weighted-average remaining lease term - operating leases (in years) 7.0 7.0 Weighted-average remaining lease term - finance leases (in years) 12.2 3.8 Weighted-average discount rate - operating leases 3.9 % 5.3 % Weighted-average discount rate - finance leases 3.5 % 2.2 % Supplemental cash flow information related to leases for fiscal years 2021 and 2020 is as follows (in thousands): 2021 2020 Cash paid for operating leases $ 10,808 $ 10,385 Cash paid for interest on finance leases 59 1 Assets acquired under operating leases 32,466 9,059 Assets acquired under finance leases 8,154 127 During the fiscal year ended December 31, 2021, the Company extended the lease terms for three of its manufacturing facilities. As a result of these lease modifications, the Company re-measured the lease liability and adjusted the ROU asset on the modification dates.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for fiscal years 2021, 2020 and 2019 (in thousands, except per share amounts): 2021 2020 2019 Numerator for basic and diluted EPS: Income from continuing operations $ 93,020 $ 77,258 $ 91,218 Income from discontinued operations 3,788 — 5,118 Net income $ 96,808 $ 77,258 $ 96,336 Denominator for basic EPS: Weighted average shares outstanding 32,993 32,845 32,627 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 265 268 410 Denominator for diluted EPS 33,258 33,113 33,037 Basic earnings per share: Income from continuing operations $ 2.82 $ 2.35 $ 2.80 Income from discontinued operations 0.11 — 0.16 Basic earnings per share 2.93 2.35 2.95 Diluted earnings per share: Income from continuing operations $ 2.80 $ 2.33 $ 2.76 Income from discontinued operations 0.11 — 0.15 Diluted earnings per share 2.91 2.33 2.92 The diluted weighted average share calculations do not include the following securities for fiscal years 2021, 2020 and 2019, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): 2021 2020 2019 Time-vested stock options, restricted stock and restricted stock units 4 98 30 Performance-vested restricted stock units 92 89 47

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Common Stock The following table sets forth the changes in the number of shares of common stock for fiscal years 2021 and 2020: Issued Treasury Stock Outstanding Shares outstanding at December 31, 2019 32,847,017 (146,546) 32,700,471 Stock options exercised 27,544 74,596 102,140 Vesting of RSUs, net of shares withheld to cover taxes 33,617 71,950 105,567 Shares outstanding at December 31, 2020 32,908,178 — 32,908,178 Stock options exercised 34,233 — 34,233 Vesting of RSUs, net of shares withheld to cover taxes 120,925 — 120,925 Shares outstanding at December 31, 2021 33,063,336 — 33,063,336 Accumulated Other Comprehensive Income Accumulated other comprehensive income comprises the following (in thousands): Defined Cash Foreign Total Tax Net-of-Tax December 31, 2019 $ (912) $ (2,358) $ 22,639 $ 19,369 $ 619 $ 19,988 Unrealized loss on cash flow hedges — (6,683) — (6,683) 1,404 (5,279) Realized loss on foreign currency hedges — 638 — 638 (134) 504 Realized loss on interest rate swap hedges — 3,447 — 3,447 (724) 2,723 Net defined benefit plan adjustments (183) — — (183) 32 (151) Foreign currency translation gain — — 34,907 34,907 — 34,907 December 31, 2020 $ (1,095) $ (4,956) $ 57,546 $ 51,495 $ 1,197 $ 52,692 Unrealized gain on cash flow hedges — 91 — 91 (19) 72 Realized gain on foreign currency hedges — (832) — (832) 175 (657) Realized loss on interest rate swap hedges — 3,406 — 3,406 (716) 2,690 Net defined benefit plan adjustments 205 — — 205 14 219 Foreign currency translation loss — — (27,826) (27,826) — (27,826) December 31, 2021 $ (890) $ (2,291) $ 29,720 $ 26,539 $ 651 $ 27,190

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and uses derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the balance sheet. The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Significant Significant December 31, 2021 Assets: Foreign currency hedging contracts $ 687 $ — $ 687 $ — Liabilities: Interest rate swap 2,978 — 2,978 — Liabilities: Contingent consideration 2,415 — — 2,415 December 31, 2020 Assets: Foreign currency hedging contracts $ 2,070 $ — $ 2,070 $ — Liabilities: Interest rate swaps 7,026 — 7,026 — Liabilities: Contingent consideration 3,900 — — 3,900 Derivatives Designated as Hedging Instruments Interest Rate Swaps The Company periodically enters into interest rate swap agreements to reduce the cash flow risk caused by interest rate changes on its outstanding floating rate borrowings. Under these swap agreements, the Company pays a fixed rate of interest and receives a floating rate equal to one-month LIBOR. The variable rate received from the swap agreements and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The Company has designated these swap agreements as cash flow hedges based on concluding the hedged forecasted transaction is probable of occurring within the period the cash flow hedge is anticipated to affect earnings. The Company receives fair value estimates from the swap agreement counterparties. The fair value of the Company’s swap agreements are determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. The Company’s interest rate swap agreements are categorized in Level 2 of the fair value hierarchy. The estimated fair value of the swap agreements represents the amount the Company would receive (pay) to terminate the contracts. Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 31, 2021 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 150,000 Jun 2020 Jun 2023 2.1785 % 0.1013 % $ (2,978) Other long-term liabilities (17.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands): Notional Amount Maturity Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun 2023 2.1785 % 0.1480 % $ (7,026) Other long-term liabilities Foreign Currency Contracts The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges. The Company receives fair value estimates from the foreign currency contract counterparties. The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Sales or Cost of Sales as the inventory, which the contracts are hedging, is sold. Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2021 is as follows (dollars in thousands): Notional Amount Maturity $/Foreign Currency Fair Value Balance Sheet Location $ 22,201 Dec 2022 0.0463 MXN Peso $ 408 Prepaid expenses and other current assets 17,017 Dec 2022 1.1344 Euro 130 Prepaid expenses and other current assets 9,020 Dec 2022 0.0220 UYU Peso 149 Prepaid expenses and other current assets Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands): Notional Amount Maturity $/Foreign Currency Fair Value Balance Sheet Location $ 16,132 Sep 2021 1.1949 Euro $ 399 Prepaid expenses and other current assets 10,224 Sep 2021 0.0454 MXN Peso 922 Prepaid expenses and other current assets 2,656 Mar 2021 0.0443 MXN Peso 341 Prepaid expenses and other current assets 7,269 Dec 2021 0.0485 MXN Peso 77 Prepaid expenses and other current assets 3,252 Aug 2021 0.0232 UYU Peso 165 Prepaid expenses and other current assets 3,966 Nov 2021 0.0227 UYU Peso 166 Prepaid expenses and other current assets The following table presents the impact of cash flow hedge derivative instruments on other comprehensive income (“OCI”), AOCI and the Company’s Consolidated Statement of Operations for fiscal years 2021, 2020 and 2019 (in thousands): Gain (Loss) Recognized in OCI Gain (Loss) Reclassified from AOCI Derivative 2021 2020 2019 Location in Statement of Operations 2021 2020 2019 Interest rate swaps $ 642 $ (7,405) $ (5,618) Interest expense $ (3,406) $ (3,447) $ 1,621 Foreign exchange contracts (943) 1,017 (1,044) Sales (674) 618 (1,334) Foreign exchange contracts 399 (355) 2,634 Cost of sales 1,437 (1,177) 1,482 Foreign exchange contracts (7) 60 — Operating expenses 69 (79) — The Company expects to reclassify net losses totaling $1.8 million related to its cash flow hedges from AOCI into earnings during the next twelve months. (17.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Derivatives Not Designated as Hedging Instruments The Company also has foreign currency exposure on balances, primarily intercompany, that are denominated in a foreign currency and are adjusted to current values using period-end exchange rates. To minimize foreign currency exposure, the Company enters into foreign currency contracts with a one month maturity. At December 31, 2021, the Company had one contract outstanding, with a notional amount of $15.0 million and a fair value of $0.1 million. The Company recorded a net gain on foreign currency contracts not designated as hedging instruments of $0.4 million for fiscal year 2021, which are included in Other (income) loss, net and generally offset the gains or losses from the foreign currency adjustments on the intercompany balances that are also included in Other (income) loss, net. Contingent Consideration The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2021 and 2020 (in thousands): December 31, 2019 $ 4,200 Amount recorded for current year acquisitions 2,700 Fair value measurement adjustment (2,000) Payments (1,000) December 31, 2020 3,900 Fair value measurement adjustment 133 Payments (1,621) Foreign currency translation 3 December 31, 2021 $ 2,415 On February 19, 2020, the Company acquired certain assets and liabilities of InoMec. On October 7, 2019, the Company acquired certain assets and liabilities of USB, a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The contingent consideration at December 31, 2021 is the estimated fair value of the Company’s obligations, under the asset purchase agreements for InoMec and USB, to make additional payments if certain revenue goals are met. See Note 2 “Business Acquisitions” for additional information about the InoMec and USB acquisitions. During 2021, the Company made payments associated with the InoMec and USB acquisitions, resulting from achievement of revenue-based goals for the period from March 1, 2020 to February 28, 2021 for InoMec and January 1, 2020 to December 31, 2020 for USB. During 2020, the Company made payments to settle a portion of a contingent consideration arrangement relating to a license to use technology. As of December 31, 2021 and December 31, 2020, the current portion of contingent consideration liabilities included in Accrued expenses and other current liabilities was $0.9 million and $1.7 million, respectively, and the non-current portion included in Other long-term liabilities on the Consolidated Balance Sheets was $1.5 million and $2.2 million, respectively. The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration: December 31, 2021 Contingency Type Remaining Maximum Payout (undiscounted) Fair Value Valuation Technique Unobservable Inputs Weighted Average or Range Revenue-based payments $ 6,750 $ 2,415 Monte Carlo Revenue volatility 29.0 % Discount rate 1.8 % Projected year(s) of payment 2022-2024 (17.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) December 31, 2020 Contingency Type Remaining Maximum Payout (undiscounted) Fair Value Valuation Technique Unobservable Inputs Weighted Average or Range Revenue-based payments $ 9,000 $ 3,900 Monte Carlo Revenue volatility 35.0 % Discount rate 4.0 % Projected year(s) of payment 2021-2024 Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, contract assets, accounts payable and accrued expenses approximate fair value due to the short-term nature of these items. Borrowings under the Company’s Revolving Credit Facility, TLA Facility and TLB Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments. Equity Investments Equity investments comprise the following (in thousands): December 31, December 31, Equity method investment $ 16,192 $ 21,470 Non-marketable equity securities 5,637 5,723 Total equity investments $ 21,829 $ 27,193 The components of (Gain) loss on equity investments, net for each period were as follows (in thousands): 2021 2020 2019 Equity method investment (income) loss $ 3,057 $ (5,706) $ (1,100) Impairment charges 86 369 1,575 Total (gain) loss on equity investments, net $ 3,143 $ (5,337) $ 475 During 2021, 2020 and 2019, the Company determined that certain non-marketable equity securities were impaired. In both 2021 and 2020, new equity financings by two of the Company’s non-marketable equity securities indicated new values for the investments. During the fourth quarters of 2021 and 2020, the Company recorded impairment charges of $0.1 million and $0.4 million, respectively, to reduce the carrying value of these non-marketable equity securities to their estimated fair value of zero and $2.2 million, respectively. The fair values of these investments were derived from observable price changes of similar securities of the investees. In 2019, the Company determined the fair value for one of its non-marketable equity securities to be zero based upon available market information. This assessment was based on qualitative indications of impairment. Factors that significantly influenced the determination of the impairment loss included the equity security’s investee’s financial condition, priority claims to the equity security, distributions rights and preferences, and status of the regulatory approval required to bring its product to market. During 2021, 2020 and 2019, the Company received cash distributions representing a return on equity method investments of $2.2 million, $0.4 million and $0.1 million, respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. As of December 31, 2021, the Company owned 6.7% of this fund.

Segment and Geographic Informat

Segment and Geographic Information	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATION The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting . The Company defines segment income from operations as sales less cost of sales including amortization and expenses attributable to segment-specific selling, general, administrative, research, development, engineering and other operating activities. The remaining unallocated operating and other expenses are primarily administrative corporate headquarter expenses and capital costs that are not allocated to reportable segments. Transactions between the two segments are not significant. The following table presents sales by product line for fiscal years 2021, 2020 and 2019 (in thousands). 2021 2020 2019 Segment sales by product line: Medical Cardio & Vascular $ 626,013 $ 569,948 $ 610,056 Cardiac & Neuromodulation 446,569 346,242 457,194 Advanced Surgical, Orthopedics & Portable Medical 110,044 121,788 132,429 Total Medical 1,182,626 1,037,978 1,199,679 Non-Medical 38,453 35,464 58,415 Total sales $ 1,221,079 $ 1,073,442 $ 1,258,094 Geographic Area Information The following table presents sales by significant country for fiscal years 2021, 2020 and 2019. In these tables, sales are allocated based on where the products are shipped (in thousands). 2021 2020 2019 Sales by geographic area: United States $ 671,502 $ 596,804 $ 698,474 Non-Domestic locations: Puerto Rico 110,162 96,048 154,644 Costa Rica 66,975 58,853 63,634 Rest of world 372,440 321,737 341,342 Total sales $ 1,221,079 $ 1,073,442 $ 1,258,094 The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for fiscal years 2021 and 2020. 2021 2020 Customer Medical Non-Medical Medical Non-Medical Customer A 19% * 19% * Customer B 17% * 17% * Customer C 14% * 15% * Customer D * 36% * 22% Customer E * * * 10% All other customers 50% 64% 49% 68% __________ * Less than 10% of segment’s total revenues for the period. (18.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for fiscal years 2021 and 2020. 2021 2020 Ship to Location Medical Non-Medical Medical Non-Medical United States 54% 71% 55% 60% Rest of world 46% 29% 45% 40% The following table presents income from continuing operations for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands). 2021 2020 2019 Segment income from continuing operations: Medical $ 213,600 $ 169,396 $ 223,873 Non-Medical 8,022 4,848 16,289 Total segment income from continuing operations 221,622 174,244 240,162 Unallocated operating expenses (85,911) (53,632) (82,527) Operating income 135,711 120,612 157,635 Unallocated expenses, net (34,648) (34,405) (52,442) Income from continuing operations before taxes $ 101,063 $ 86,207 $ 105,193 The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands). 2021 2020 2019 Segment depreciation and amortization: Medical $ 75,366 $ 72,338 $ 68,867 Non-Medical 1,167 996 1,039 Total depreciation and amortization included in segment income from continuing operations 76,533 73,334 69,906 Unallocated depreciation and amortization 4,836 5,990 7,989 Total depreciation and amortization $ 81,369 $ 79,324 $ 77,895 The following table presents total assets for the Company’s reportable segments as of December 31, 2021 and December 31, 2020 (in thousands). December 31, December 31, Identifiable assets: Medical $ 2,448,123 $ 2,212,489 Non-Medical 56,158 52,682 Total reportable segments 2,504,281 2,265,171 Unallocated assets 77,934 106,686 Total assets $ 2,582,215 $ 2,371,857 (18.) SEGMENT AND GEOGRAPHIC INFORMATION (Continued) The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands). 2021 2020 2019 Expenditures for tangible long-lived assets: Medical $ 48,364 $ 42,435 $ 44,026 Non-Medical 628 1,038 397 Total reportable segments 48,992 43,473 44,423 Unallocated long-lived tangible assets 4,471 3,359 3,775 Total expenditures $ 53,463 $ 46,832 $ 48,198 The following table presents PP&E by geographic area as of December 31, 2021 and December 31, 2020. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands). December 31, December 31, Long-lived tangible assets by geographic area: United States $ 184,474 $ 170,871 Mexico 33,877 32,723 Ireland 41,501 38,526 Rest of world 17,247 11,844 Total $ 277,099 $ 253,964

Revenue From Contracts With Cus

Revenue From Contracts With Customers	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregated Revenue In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 18, “Segment and Geographic Information.” A significant portion of the Company’s sales for fiscal years 2021, 2020 and 2019 and accounts receivable at December 31, 2021 and December 31, 2020 were to three customers as follows: Sales Accounts Receivable 2021 2020 2019 December 31, December 31, Customer A 18% 18% 21% 15% 15% Customer B 16% 16% 17% 19% 19% Customer C 13% 14% 12% 10% 13% 47% 48% 50% 44% 47% Revenue recognized from products and services transferred to customers over time during fiscal years 2021 and 2020 represented 33% and 29%, respectively, of total revenue. Substantially all of the revenue recognized from products and services transferred to customers over time during fiscal years 2021 and 2020 was within the Medical segment. (19.) REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued) Contract Balances The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands): December 31, December 31, Contract assets $ 64,743 $ 40,218 Contract liabilities 3,776 2,498 Contract assets at December 31, 2021, increased $24.5 million from December 31, 2020, primarily due to a contract modification to add existing products and extend the contractual term. During the fiscal year ended December 31, 2021, the Company recognized $1.9 million of revenue that was included in the contract liability balance as of December 31, 2020. During the fiscal year ended December 31, 2020, the Company recognized $1.3 million of revenue that was included in the contract liability balance as of December 31, 2019.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	DISCONTINUED OPERATIONS Divestiture of AS&O Product Line In July 2018, the Company completed the sale of its AS&O Product Line within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. During the fourth quarter of 2021, the Company recognized other income from discontinued operations of $4.9 million for the release of pre-divestiture indemnified tax liabilities resulting from the lapse of the statute of limitations and the effective settlement of tax audits. During 2019, the Company received, and recognized as gain on sale from discontinued operations, $4.8 million due to the final net working capital adjustment agreed to with Viant. Income from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands): 2021 2020 2019 Gain on sale of discontinued operations $ — $ — $ (4,974) Other income, net (4,931) — (322) Income from discontinued operations before taxes 4,931 — 5,296 Provision for income taxes 1,143 — 178 Income from discontinued operations $ 3,788 $ — $ 5,118 Cash flow information from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands): 2021 2020 2019 Cash used in operating activities $ — $ — $ (78) Cash provided by investing activities — — 4,734

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts	Schedule II—Valuation and Qualifying Accounts Col. C—Additions Column A Col. B Balance at Beginning Charged to Costs & Charged to Other Accounts- Describe Col. D Deductions Col. E Balance at End of December 31, 2021 Provision for credit losses $ 155 $ 20 (1) $ — $ (43) (4) $ 132 Valuation allowance for deferred tax assets $ 20,739 $ (941) (2) $ 26 (3) $ (368) (2) $ 19,456 December 31, 2020 Provision for credit losses $ 2,443 $ 28 (1) $ — $ (2,316) (4) $ 155 Valuation allowance for deferred tax assets $ 22,229 $ (275) (2) $ — $ (1,215) (2)(4)(5) $ 20,739 December 31, 2019 Allowance for doubtful accounts $ 592 $ 1,884 (1) $ 2 (3) $ (35) (4) $ 2,443 Valuation allowance for deferred tax assets $ 34,339 $ 736 (2) $ — $ (12,846) (2)(4)(5) $ 22,229 (1) Valuation allowance recorded in the provision for credit losses (allowance for doubtful accounts in years prior to 2020). The 2019 amount includes a $2.3 million reserve recorded in connection with a customer bankruptcy, net of adjustments to the Company’s general and specific reserves. (2) Valuation allowance recorded in the provision for income taxes for certain net operating losses and tax credits. The 2021, 2020 and 2019 deductions include the expiration of certain net operating losses and tax credits. (3) Includes foreign currency translation effect. (4) Accounts written off and reductions to allowances existing at the beginning of the year. The 2020 amount includes $2.3 million of accounts receivable recorded during 2019 in connection with a customer bankruptcy. (5) The 2020 and 2019 deductions include releases of the allowance for net operating losses utilized during that year and return to provision adjustments for prior years. Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. (3) See exhibits listed under Part (b) below.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and include the accounts of Integer Holdings Corporation and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In July 2018, the Company completed the sale of its Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) within its Medical segment to Viant (formerly MedPlast, LLC). For all periods presented, financial results reported as discontinued operations in the Consolidated Statements of Operations relate to the divested AS&O Product Line. The Consolidated Statements of Cash Flows includes cash flows related to the discontinued operations due to Integer’s (parent) centralized treasury and cash management processes. See Note 20 “Discontinued Operations” for the financial results and cash flow amounts for discontinued operations. All results and information in the consolidated financial statements are presented as continuing operations and exclude the AS&O Product Line unless otherwise noted specifically as discontinued operations. The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. The discontinued operations of the AS&O Product Line were reported in the Medical segment. Refer to Note 18 “Segment and Geographic Information,” for additional information on the Company’s reportable segments.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of sales and expenses during the reporting periods. Actual results could differ materially from those estimates.
Cash and Cash Equivalents	Cash and Cash EquivalentsCash and cash equivalents consist of cash and highly liquid, short-term investments with maturities at the time of purchase of three months or less.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of accounts receivable. A significant portion of the Company’s sales and accounts receivable are to three customers, all in the medical device industry, and, as such, the Company is directly affected by the condition of those customers and that industry. However, the credit risk associated with trade receivables is partially mitigated due to the stability of those customers. The Company performs on-going credit evaluations of its customers. Note 19 “Revenue from Contracts with Customers” contains information on sales and accounts receivable for these customers. The Company maintains cash deposits with major banks, which from time to time may exceed insured limits. The Company performs on-going credit evaluations of its banks.
Trade Accounts Receivable and Provision for Current Expected Credit Losses	Trade Accounts Receivable and Provision for Current Expected Credit LossesThe Company provides credit, in the normal course of business, to its customers in the form of trade receivables. Credit is extended based on evaluation of a customer’s financial condition and collateral is not required. The Company maintains a provision for those customer receivables that it does not expect to collect. In accordance with Accounting Standards Codification (“ASC”) Topic 326, the Company accrues its estimated losses from uncollectable accounts receivable to the provision based upon recent historical experience, the length of time the receivable has been outstanding, other specific information as it becomes available, and reasonable and supportable forecasts not already reflected in the historical loss information. Provisions for current expected credit losses are charged to current operating expenses. Actual losses are charged against the provision when incurred.
Supplier Financing Arrangements	Supplier Financing ArrangementsThe Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreements transfer control and risk related to the receivables to the financial institutions. The Company has no continuing involvement in the transferred receivables subsequent to the sale.
Inventories	InventoriesInventories are stated at the lower of cost, determined using the first-in first-out method, or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Write-downs for excess, obsolete or expired inventory are based primarily on how long the inventory has been held, historical sales volume, and estimates of forecasted net sales of that product. A significant change in the timing or level of demand for products may result in recording additional write-downs for excess, obsolete or expired inventory in the future. Note 4 “Inventories” contains additional information on the Company’s inventory.
Leases	Leases The Company determines if an arrangement is, or contains, a lease at inception and classifies it at as finance or operating. The Company has operating and finance leases for office and manufacturing facilities, machinery, computer hardware, office equipment, and vehicles. Finance lease assets and corresponding liabilities are included in Other long-term assets, Accrued expenses and other current liabilities, and Other long-term liabilities, respectively, on the Consolidated Balance Sheets. Lease right-of-use (“ROU”) assets and corresponding liabilities are recognized based on the present value of the lease payments over the lease term at commencement date. When discount rates implicit in leases cannot be readily determined, the Company uses its incremental borrowing rate based on information available at commencement date in determining the present value of future payments. The incremental borrowing rate is determined based on the Company’s recent debt issuances, the Company’s specific credit rating, lease term and the currency in which lease payments are made. (1.) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued) Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such option. Costs associated with operating leases are recognized within operating expenses on a straight-line basis over the lease term. Finance lease assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or, in the instance where title does not transfer at the end of the lease term, the lease term. The interest component of a finance lease is included in Interest expense and recognized using the effective interest method over the lease term. The Company combines lease and non-lease components for all asset classes. For certain leases where rent escalates based upon a change in a financial index, such as the Consumer Price Index, the difference between the rate at lease inception and the subsequent fluctuations in that rate are included in variable lease costs. Additionally, because the Company does not separate lease and non-lease components, variable costs also include payments to the landlord for common area maintenance, real estate taxes, insurance and other operating expenses. The Company does not apply the recognition requirements to leases with lease terms of 12 months or less. Note 14 “Leases” contains additional information on the Company’s leases.
Property, Plant and Equipment	Property, Plant and Equipment (“PP&E”) PP&E is carried at cost less accumulated depreciation. Depreciation is computed by the straight-line method over the estimated useful lives of the assets, as follows: buildings and building improvements 12-30 years; machinery and equipment 3-10 years; office equipment 3-10 years; and leasehold improvements over the remaining lives of the improvements or the lease term, whichever is shorter. The costs of repairs and maintenance are expensed as incurred; renewals and betterments are capitalized. Upon retirement or sale of an asset, its cost and related accumulated depreciation or amortization is removed from the accounts and any gain or loss is recorded in operating income or expense. The Company also reviews its PP&E for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its fixed assets exceeds the related undiscounted future cash flows. In cases where the carrying value of the Company's long-lived assets or asset groups (excluding goodwill and indefinite-lived intangible assets) exceeds the related undiscounted cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. Note 5 “Property, Plant and Equipment, Net” contains additional information on the Company’s PP&E.
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e . the “exit price”) in an orderly transaction between market participants at the measurement date. ASC 820, Fair Value Measurements, establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the reliability of inputs as follows: Level 1 – Valuation is based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 1 valuations do not entail a significant degree of judgment. Level 2 – Valuation is determined from quoted prices for similar assets or liabilities in active markets, quoted prices for identical instruments in markets that are not active or by model-based techniques in which all significant inputs are observable in the market. Level 3 – Valuation is based on unobservable inputs that are significant to the overall fair value measurement. The degree of judgment in determining fair value is greatest for Level 3 valuations. Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, assumptions are required to reflect those that market participants would use in pricing the asset or liability at the measurement date. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on assets and liabilities recorded at fair value in the consolidated financial statements.
Acquisitions and Contingent Consideration	Acquisitions The Company accounts for acquisitions under the acquisition method of accounting for business combinations. Results of operations of acquired companies are included in the Company’s results of operations as of the respective acquisition dates. The purchase price of each acquisition is allocated to the net assets acquired based on estimates of their fair values at the date of the acquisition. Any purchase price in excess of these net assets is recorded as goodwill. All direct acquisition-related costs are expensed as incurred and are recognized as a component of Other operating expenses. The allocation of purchase price in certain cases may be subject to revision based on the final determination of fair values during the measurement period, which may be up to one year from the acquisition date. Contingent Consideration In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable performance target. Increases in projected revenues, estimated cash flows and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates in periods prior to payment may result in significantly lower fair value measurements and decreases in the discount rates may have the opposite effect. The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The Company determines the initial fair value of contingent consideration liabilities using a Monte Carlo (“Monte Carlo”) valuation model, which involves a simulation of future revenues during the earn out-period using management’s best estimates, or a probability-weighted discounted cash flow analysis. In periods subsequent to the initial measurement, contingent consideration liabilities are remeasured to fair value each reporting period until the contingent consideration is settled using various assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, revenue volatility and projected payment dates. The current portion of contingent consideration liabilities is included in Accrued expenses and other current liabilities and the non-current portion is included in Other long-term liabilities on the Consolidated Balance Sheets. Adjustments to the fair value of contingent consideration liabilities are included in Other operating expenses in the Consolidated Statements of Operations, and cash flows from operating activities in the Consolidated Statements of Cash Flows. Note 17 “Financial Instruments and Fair Value Measurements” contains additional information on contingent consideration recorded at fair value in the consolidated financial statements.
Goodwill	Goodwill Goodwill represents the excess of cost over the fair value of identifiable net assets of a business acquired and is assigned to one or more reporting units. The Company’s reporting units are the same as its reportable segments, Medical and Non-Medical. The Company tests each reporting unit’s goodwill for impairment at least annually as of the last day of the fiscal year and between annual tests if an event occurs or circumstances change that would more-likely-than-not reduce the fair value of a reporting unit below its carrying amount. In conducting its goodwill test, the Company either performs a qualitative assessment or a quantitative assessment. A qualitative assessment requires that the Company consider events or circumstances including, but not limited to, macro-economic conditions, market and industry conditions, cost factors, competitive environment, changes in strategy, changes in customers, changes in the Company’s stock price, results of the last impairment test, and the operational stability and the overall financial performance of the reporting units. If, after assessing the totality of events or circumstances, the Company determines that it is more likely than not that the fair values of its reporting units are greater than the carrying amounts, then the quantitative goodwill impairment test is not performed. The Company may elect to bypass the qualitative analysis and perform a quantitative analysis. If the qualitative assessment indicates that the quantitative analysis should be performed or if management elects to bypass a qualitative analysis to perform a quantitative analysis, the Company then evaluates goodwill for impairment by comparing the fair value of each of its reporting units to its carrying value, including the associated goodwill. To determine the fair values, the Company uses a weighted combination of the market approach based on comparable publicly traded companies and the income approach based on estimated discounted future cash flows. The cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors.
Other Intangible Assets	Other Intangible Assets Other intangible assets consist of purchased technology and patents, customer lists and trademarks. Definite-lived intangible assets are amortized on an accelerated or straight-line basis, which approximates the projected cash flows used to determine the fair value of those definite-lived intangible assets at the time of acquisition, as follows: purchased technology and patents 5-20 years; customer lists 7-20 years and other intangible assets 1-20 years. Certain trademark assets are considered indefinite-lived intangible assets and are not amortized. The Company expenses the costs incurred to renew or extend the term of intangible assets. The Company reviews its definite-lived intangible assets for impairment when impairment indicators exist. When impairment indicators exist, the Company determines if the carrying value of its definite-lived intangible assets or asset groups exceeds the related undiscounted future cash flows. In cases where the carrying value exceeds the undiscounted future cash flows, the carrying value is written down to fair value. Fair value is generally determined using a discounted cash flow analysis. The Company assesses its indefinite-lived intangible assets for impairment periodically to determine if any adverse conditions exist that would indicate impairment or when impairment indicators exist. The Company assesses its indefinite-lived intangible assets for impairment at least annually by comparing the fair value of the indefinite-lived intangible asset to its carrying value. The fair value is determined using the relief from royalty method. Refer to Note 6 “Goodwill and Other Intangible Assets, Net” for further details of the Company’s goodwill and other intangible assets.
Equity Investments	Equity Investments The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Consolidated Balance Sheets. Equity investments are measured and recorded as follows: • Non-marketable equity securities are equity securities without readily determinable fair value that are measured and recorded at fair value with changes in fair value recognized within net income. The Company measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs. • Equity method investments are equity securities in investees the Company does not control but over which it has the ability to exercise influence. Equity method investments are recorded at cost and are adjusted to recognize (1) the Company’s share, based on percentage ownership or other contractual basis, of the investee’s income or loss, (2) additional contributions made and dividends or other distributions received, and (3) impairments resulting from other-than-temporary declines in fair value. Realized and unrealized gains and losses resulting from changes in fair value or the sale of these equity investments are recorded through (Gain) loss on equity investments, net. For some investments, the Company records its share of the investee’s income or loss one quarter in arrears due to the timing of our receipt of such information. The carrying value of the Company’s non-marketable equity securities is adjusted for qualifying observable price changes resulting from the issuance of similar or identical securities by the same issuer. Determining whether an observed transaction is similar to a security within the Company’s portfolio requires judgment based on the rights and preferences of the securities. Recording upward and downward adjustments to the carrying value of the Company’s equity securities as a result of observable price changes requires quantitative assessments of the fair value of these securities using various valuation methodologies and involves the use of estimates. Non-marketable equity securities and equity method investments (collectively referred to as non-marketable equity investments) are also subject to periodic impairment reviews. The Company’s quarterly impairment analysis considers both qualitative and quantitative factors that may have a significant impact on the investee’s fair value. Qualitative factors considered include the investee’s financial condition and business outlook, market for technology, operational and financing cash flow activities, technology and regulatory approval progress, and other relevant events and factors affecting the investee. When indicators of impairment exist, quantitative assessments of the fair value of the Company’s non-marketable equity investments are prepared. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. Non-marketable equity securities are tested for impairment using a qualitative model similar to the model used for goodwill and long-lived assets. Upon determining that an impairment may exist, the security’s fair value is calculated and compared to its carrying value and an impairment is recognized immediately if the carrying value exceeds the fair value. Equity method investments are subject to periodic impairment reviews using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and the Company’s ability and intent to hold the investment for a sufficient period of time to allow for recovery. The Company has determined that its investments are not considered variable interest entities. The Company’s exposure related to these entities is limited to its recorded investment. These investments are in start-up research and development companies whose fair value is highly subjective in nature and subject to future fluctuations, which could be significant. Refer to Note 17 “Financial Instruments and Fair Value Measurements” for additional information on the Company’s equity investments.
Debt Issuance Costs and Discounts	Debt Issuance Costs and Discounts Debt issuance costs and discounts associated with the issuance of debt by the Company are deferred and amortized over the lives of the related debt. Debt issuance costs incurred in connection with the Company’s issuance of its revolving credit facility are classified within Other long-term assets and amortized to Interest expense on a straight-line basis over the contractual term of the revolving credit facility. Debt issuance costs and discounts related to the Company’s term-debt are recorded as a reduction of the carrying value of the related debt and are amortized to Interest expense using the effective interest method over the period from the date of issuance to the maturity date. Upon prepayment of the related debt, the Company also recognizes a proportionate amount of the costs as extinguishment of debt. Costs treated as extinguishment of debt are expensed and included in Interest expense in the accompanying Consolidated Statements of Operations. The amortization of debt issuance costs and discounts, and debt extinguishment charges are included in Debt related charges included in interest expense in the Consolidated Statements of Cash Flows. Note 8 “Debt” contains additional information on the Company’s debt issuance costs and discounts.
Income Taxes	Income Taxes The consolidated financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided on deferred tax assets if it is determined, within each taxing jurisdiction, that it is more likely than not that the asset will not be realized. The Company accounts for uncertain tax positions using a more likely than not recognition threshold. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. These tax positions are evaluated on a quarterly basis. The Company recognizes interest expense related to uncertain tax positions as Provision for income taxes. Penalties, if incurred, are recognized as a component of Selling, general and administrative (“SG&A”) expenses. The Company and its subsidiaries file a consolidated United States (“U.S.”) federal income tax return. State tax returns are filed on a combined or separate basis depending on the applicable laws in the jurisdictions where the tax returns are filed. The Company also files foreign tax returns on a separate company basis in the countries in which it operates.
Derivative Financial Instruments	Derivative Financial Instruments The Company recognizes all derivative financial instruments in its consolidated financial statements at fair value .
Revenue Recognition	Revenue Recognition The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The majority of contracts have an original expected duration of one year or less. Consideration payable to customers is included in the transaction price. In accordance with ASC 340-40-25-4, the Company expenses incremental costs of obtaining a contract when incurred because the amortization period is less than one year. The Company evaluates revenue recognition in contracts with customers as performance obligations are satisfied and as the customer obtains control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the products. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Most of the Company’s revenues are recognized at the point in time when the products are shipped to customers. When contracts with customers for products, which do not have an alternative use to the Company, contain provisions that provide the Company with an enforceable right to payment for performance completed to date for costs incurred plus a reasonable profit throughout the duration of the contract, revenue is recognized over time as control is transferred to the customer. In contracts with customers where revenue is recognized over time, the Company uses an input measure to determine progress towards completion and total estimated costs at completion. Under this method, sales and gross profit are recognized as work is performed generally based on actual costs incurred. Revenue is recognized net of sales tax, value-added taxes and other taxes. Performance Obligations The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and may include a discount for early payment. The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities are classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. For contracts with customers where revenue is recognized over time, the Company records a contract asset for unbilled revenue associated with non-cancellable customer orders, which is recorded within Contract assets on the Consolidated Balance Sheets. Transaction Price Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and are updated quarterly. Adjustments to these estimates are recognized under the cumulative catch-up method and in the period in which they are identified. When contracts with customers include consideration payable at the beginning of the contract, the transaction price is reduced at the later of when the Company recognizes revenue for the transfer of the related goods to the customer or when the Company pays or promises to pay the consideration. Volume discounts and rebates and other pricing reductions earned by customers are offset against their receivable balances. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price. Contract Modifications
Environmental Costs	Environmental Costs Environmental expenditures that relate to an existing condition caused by past operations and that do not provide future benefits are expensed as incurred. Liabilities are recorded when environmental assessments are made, the requirement for remedial efforts is probable and the amount of the liability can be reasonably estimated. Liabilities are recorded generally no later than the completion of feasibility studies. The Company has a process in place to monitor, identify, and assess how the current activities for known exposures are progressing against the recorded liabilities. The process is also designed to identify other potential remediation sites that are not presently known.
Restructuring Expenses	Restructuring Expenses The Company continually evaluates alternatives to align its resources with the changing needs of its customers and markets, and to lower its operating costs. This includes realignment of existing manufacturing capacity, facility closures, process optimization, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in voluntary or involuntary employee termination benefits. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. All other exit costs are expensed as incurred. Refer to Note 11 “Other Operating Expenses” for additional information.
Research, Development and Engineering (RD&E)	Research, Development and Engineering (“RD&E”)RD&E costs are expensed as incurred. The primary costs are salary and benefits for personnel, material costs used in development projects and subcontracting costs.
Product Warranties	Product Warranties The Company allows customers to return defective or damaged products for credit, replacement, or repair. The Company warrants that its products will meet customer specifications and will be free from defects in materials and workmanship . The Company accrues its estimated exposure to warranty claims, through Cost of Sales, based upon experience and other specific information as it becomes available. The product warranty liability is classified as Accrued expenses and other current liabilities on the Consolidated Balance Sheets. Adjustments to pre-existing estimated exposure for warranties are made as changes to the obligations become reasonably estimable. Note 13 “Commitments and Contingencies” contains additional information on the Company’s product warranties.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense for its compensation plans. These plans include stock options, restricted stock units (“RSUs”) and performance-based restricted stock units (“PRSUs”). For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of targets based on market conditions, such as total shareholder return, or performance conditions based on the Company’s operating results. The Company records forfeitures of equity awards in the period in which they occur. The fair value of the stock-based compensation is determined at the grant date. The Company uses the Black-Scholes standard option pricing model (“Black-Scholes model”) to determine the fair value of stock options. The fair value of each RSU is determined based on the Company’s closing stock price on the date of grant. The fair value of each PRSU is determined based on either the Company’s closing stock price on the date of grant or through a Monte Carlo valuation model for those awards that include a market-based condition. In addition to the closing stock price on the date of grant, the determination of the fair value of awards using both the Black-Scholes and Monte Carlo valuation models is affected by other assumptions, including the following: Expected Term - The Company analyzes historical employee exercise and termination data to estimate the expected term assumption for stock options. For market-based awards, the term is commensurate with the performance period remaining as of the grant date. Risk-free Interest Rate - A risk-free rate is based on the U.S. Treasury rates in effect on the grant date for a maturity equal to or approximating the expected term of the award. Expected Volatility - For stock options, expected volatility is calculated using historical volatility based on the daily closing prices of the Company’s common stock over a period equal to the expected term. For market-based awards, a combination of historical and implied volatility for the Company and members of its peer group are used in developing the expected volatility assumption. Dividend Yield - The dividend yield assumption is based on the Company’s expected annual dividend yield on the grant date. The Company recognizes compensation expense over the required service or vesting period based on the fair value of the award on the date of grant. Certain executive stock-based awards contain market, performance and service conditions. Compensation expense for awards with market conditions is recognized over the service period and is not reversed if the market condition is not met. Compensation expense for awards with performance conditions is reassessed each reporting period and recognized based upon the probability that the performance targets will be achieved. All stock option awards granted under the Company’s compensation plans have an exercise price equal to the closing stock price on the date of grant, a ten-year contractual life and generally, vest annually over a three-year vesting term. RSUs typically vest in equal annual installments over a three The Company records deferred tax assets for awards that result in deductions on the Company’s income tax returns, based on the amount of stock-based compensation expense recognized and the statutory tax rate in the jurisdiction in which it will receive a deduction. Differences between the deferred tax assets recognized for financial reporting purposes and the actual tax deduction reported on the income tax return are recorded as a component of Provision for income taxes in the Consolidated Statements of Operations. Note 10 “Stock-Based Compensation” contains additional information on the Company’s stock-based compensation.
Defined Benefit Plans	Defined Benefit Plans The Company recognizes in its balance sheet as an asset or liability the overfunded or underfunded status of its defined benefit plans provided to its employees located in Mexico and Switzerland. This asset or liability is measured as the difference between the fair value of plan assets, if any, and the benefit obligation of those plans. For these plans, the benefit obligation is the projected benefit obligation, which is calculated based on actuarial computations of current and future benefits for employees. Actuarial gains or losses and prior service costs or credits that arise during the period, but are not included as components of net periodic benefit expense, are recognized as a component of AOCI on the Consolidated Balance Sheets. The Company records the service cost component of net benefit costs in Cost of sales and SG&A expenses. The interest cost component of net benefit costs is recorded in Interest expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are recorded in Other (income) loss, net.
Foreign Currency Translation and Remeasurement	Foreign Currency Translation and Remeasurement The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translates income and expenses at the average exchange rates in effect during the period. The net effect of this translation is recorded in the consolidated financial statements as a component of AOCI. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in the Company’s foreign subsidiaries.
Earnings Per Share (EPS)	Earnings Per Share (“EPS”) Basic EPS is calculated by dividing Net Income by the weighted average number of shares outstanding during the period. Diluted EPS is calculated by adjusting the weighted average number of shares outstanding for potential common shares if dilutive to the EPS calculation. Note 15 “Earnings Per Share” contains additional information on the computation of the Company’s EPS.
Comprehensive Income	Comprehensive Income The Company’s comprehensive income as reported in the Consolidated Statements of Comprehensive Income includes net income, foreign currency translation adjustments, the net change in cash flow hedges, net of tax, and defined benefit plan liability adjustments, net of tax. The Consolidated Statements of Comprehensive Income and Note 16 “Stockholders’ Equity” contain additional information on the computation of the Company’s comprehensive income.
Recently Accounting Pronouncements Adopted, Accounting Guidance Not Yet Elected or Adopted	Recent Accounting Pronouncements In the normal course of business, management evaluates all new Accounting Standards Updates (“ASU”) and other accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Consolidated Financial Statements. Except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements. Accounting Guidance Not Yet Elected or Adopted In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which creates an exception to the general recognition and measurement principle in ASC 805 by requiring companies to apply ASC 606 to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. The guidance additionally clarifies that companies should apply the definition of a performance obligation in ASC 606 when recognizing contract liabilities assumed in a business combination. The Company will early adopt ASU 2021-08 as of January 1, 2022 on a prospective basis. The impact of the adoption of ASU 2021-08 cannot currently be determined, as it is dependent on future business combinations that the Company may enter into.

Business Acquisition (Tables)

Business Acquisition (Tables)	12 Months Ended
	Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Schedule of Summary of Final Allocation of Purchase Consideration	As a result, the allocation of the provisional purchase price may change in the future, which could be material. The preliminary purchase price allocation was as follows (in thousands): Fair value of net assets acquired Current assets (excluding inventory) $ 12,148 Inventory 12,212 Property, plant and equipment 17,977 Goodwill 77,887 Intangible assets 105,300 Operating lease assets 15,142 Other noncurrent assets 695 Current liabilities (8,875) Operating lease liabilities (12,044) Fair value of net assets acquired $ 220,442
Schedule of Indefinite-Lived Intangible Assets	The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Weighted Average Discount Rate Customer lists $ 73,800 20.0 9.5% Technology 15,200 15.0 9.5% Tradenames 16,300 20.0 9.5% Intangible assets comprise the following (in thousands): Gross Accumulated Net December 31, 2021 Definite-lived: Purchased technology, tradenames and patents $ 285,659 $ (164,371) $ 121,288 Customer lists 783,618 (187,412) 596,206 Other 4,162 (4,134) 28 Total amortizing intangible assets $ 1,073,439 $ (355,917) $ 717,522 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2020 Definite-lived: Purchased technology and patents $ 257,453 $ (152,798) $ 104,655 Customer lists 723,791 (161,856) 561,935 Other 4,142 (3,796) 346 Total amortizing intangible assets $ 985,386 $ (318,450) $ 666,936 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Business Acquisition, Pro Forma Information	The following unaudited pro forma information presents the consolidated results of operations of the Company and Oscor as if the acquisition occurred as of the beginning of fiscal year 2020 (in thousands): 2021 2020 Sales $ 1,274,148 $ 1,128,137 Income from continuing operations $ 91,844 $ 67,529

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The following represents supplemental cash flow information for fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Non-cash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 5,556 $ 3,597 $ 8,646 Cash paid during the year for: Interest 24,740 33,933 44,784 Income taxes 19,649 18,477 30,034

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories comprise the following (in thousands): December 31, December 31, Raw materials $ 70,956 $ 72,477 Work-in-process 74,152 58,806 Finished goods 10,591 18,040 Total $ 155,699 $ 149,323

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	PP&E comprises the following (in thousands): December 31, 2021 December 31, Manufacturing machinery and equipment $ 352,391 $ 320,807 Buildings and building improvements 98,007 102,037 Information technology hardware and software 72,752 69,969 Leasehold improvements 85,931 77,382 Furniture and fixtures 17,099 16,250 Land and land improvements 13,980 11,598 Construction work in process 41,813 26,389 Other 1,431 1,238 683,404 625,670 Accumulated depreciation (406,305) (371,706) Total $ 277,099 $ 253,964
Schedule of Depreciation Expense	Depreciation expense for PP&E was as follows for fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Depreciation expense $ 39,772 $ 38,193 $ 37,819

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The change in the carrying amount of goodwill by reportable segment during fiscal years 2021 and 2020 was as follows (in thousands): Medical Non-Medical Total December 31, 2019 $ 822,617 $ 17,000 $ 839,617 Acquisition 4,800 — 4,800 Acquisition-related adjustments (Note 2) (85) — (85) Foreign currency translation 15,110 — 15,110 December 31, 2020 842,442 17,000 859,442 Acquisition (Note 2) 77,887 — 77,887 Foreign currency translation (12,625) — (12,625) December 31, 2021 $ 907,704 $ 17,000 $ 924,704
Schedule of Finite-Lived Intangible Assets	Intangible assets comprise the following (in thousands): Gross Accumulated Net December 31, 2021 Definite-lived: Purchased technology, tradenames and patents $ 285,659 $ (164,371) $ 121,288 Customer lists 783,618 (187,412) 596,206 Other 4,162 (4,134) 28 Total amortizing intangible assets $ 1,073,439 $ (355,917) $ 717,522 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2020 Definite-lived: Purchased technology and patents $ 257,453 $ (152,798) $ 104,655 Customer lists 723,791 (161,856) 561,935 Other 4,142 (3,796) 346 Total amortizing intangible assets $ 985,386 $ (318,450) $ 666,936 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Indefinite-Lived Intangible Assets	The purchase price was allocated to intangible assets as follows (dollars in thousands): Definite-lived Intangible Assets Fair Value Assigned Weighted Average Amortization Period Weighted Average Discount Rate Customer lists $ 73,800 20.0 9.5% Technology 15,200 15.0 9.5% Tradenames 16,300 20.0 9.5% Intangible assets comprise the following (in thousands): Gross Accumulated Net December 31, 2021 Definite-lived: Purchased technology, tradenames and patents $ 285,659 $ (164,371) $ 121,288 Customer lists 783,618 (187,412) 596,206 Other 4,162 (4,134) 28 Total amortizing intangible assets $ 1,073,439 $ (355,917) $ 717,522 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2020 Definite-lived: Purchased technology and patents $ 257,453 $ (152,798) $ 104,655 Customer lists 723,791 (161,856) 561,935 Other 4,142 (3,796) 346 Total amortizing intangible assets $ 985,386 $ (318,450) $ 666,936 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense comprises the following for fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Cost of sales $ 13,090 $ 12,860 $ 13,111 SG&A 28,507 28,271 26,965 Total intangible asset amortization expense $ 41,597 $ 41,131 $ 40,076
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based upon the carrying value as of December 31, 2021 is as follows (in thousands): 2022 2023 2024 2025 2026 After 2026 Amortization expense $ 46,594 $ 48,490 $ 47,576 $ 45,946 $ 43,612 $ 485,304

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Accounts Payable and Accrued Liabilities [Abstract]
Schedule of Accrued Liabilities and Other Current Liabilities	Accrued expenses and other current liabilities comprise the following (in thousands): December 31, 2021 December 31, Salaries and benefits $ 27,733 $ 24,512 Profit sharing and bonuses 18,325 19,204 Contract liabilities 3,776 2,498 Product warranties 509 163 Accrued interest 76 1,644 Other 6,514 8,822 Total $ 56,933 $ 56,843

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Debt	Long-term debt comprises the following (in thousands): December 31, 2021 December 31, Senior secured term loan A $ 467,062 $ 229,687 Senior secured term loan B 349,125 508,286 Senior secured revolving credit facility 19,300 — Unamortized discount on term loan B and deferred debt issuance costs (7,361) (6,715) Total debt 828,126 731,258 Current portion of long-term debt (15,250) (37,500) Total long-term debt $ 812,876 $ 693,758
Schedule of Maturities of Long-term Debt	for the next five years and thereafter, as of December 31, 2021, are as follows (in thousands): 2022 2023 2024 2025 2026 After 2026 Future minimum principal payments $ 15,250 $ 18,188 $ 29,938 $ 38,750 $ 401,739 $ 331,622
Schedule of Deferred Financing Costs	The change in deferred debt issuance costs related to the Company’s Revolving Credit Facility is as follows (in thousands): December 31, 2020 891 Financing costs incurred 2,762 Write-off of deferred debt issuance costs (72) Amortization during the period (542) December 31, 2021 $ 3,039 The change in unamortized discount and deferred debt issuance costs related to the Term Loan Facilities is as follows (in thousands): Deferred Debt Issuance Costs Unamortized Discount on TLB Facility Total December 31, 2020 5,258 1,457 6,715 Financing costs incurred 5,236 1,750 6,986 Write-off of deferred debt issuance costs and unamortized discount (2,677) (954) (3,631) Amortization during the period (2,143) (566) (2,709) December 31, 2021 $ 5,674 $ 1,687 $ 7,361

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense for fiscal years 2021, 2020 and 2019 were as follows (in thousands): 2021 2020 2019 Stock options $ — $ 43 $ 410 RSUs and PRSUs 16,185 9,120 8,884 Total stock-based compensation expense $ 16,185 $ 9,163 $ 9,294 Cost of sales $ 3,365 $ 1,658 $ 1,011 SG&A 11,579 6,942 7,827 RD&E 969 563 269 OOE 272 — 187 Total stock-based compensation expense $ 16,185 $ 9,163 $ 9,294
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes stock option activity during the fiscal year ended December 31, 2021: Number of Weighted Weighted Aggregate Outstanding at December 31, 2020 281,873 $ 36.05 Exercised (34,233) 21.72 Outstanding at December 31, 2021 247,640 $ 38.03 4.2 $ 11.8 Vested and exercisable at December 31, 2021 247,640 $ 38.03 4.2 $ 11.8
Schedule Of Stock Option Exercise Information	The following table provides certain information relating to the exercise of stock options during fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Intrinsic value $ 2,370 $ 4,773 $ 7,998 Cash received 743 3,263 3,242
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes RSU activity during the fiscal year ended December 31, 2021: Time-Vested Weighted Nonvested at December 31, 2020 207,923 $ 75.38 Granted 208,624 81.98 Vested (149,464) 74.47 Forfeited (18,952) 79.84 Nonvested at December 31, 2021 248,131 $ 81.14 The following table summarizes PRSU activity during the fiscal year ended December 31, 2021: Performance- Weighted Nonvested at December 31, 2020 219,391 $ 72.33 Granted 92,384 85.16 Vested (38,882) 37.75 Forfeited (74,024) 53.45 Nonvested at December 31, 2021 198,869 $ 92.07
Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions	The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows: 2021 2020 2019 Weighted average fair value $ 85.16 $ 107.27 $ 117.03 Risk-free interest rate 0.19 % 1.29 % 2.46 % Expected volatility 41 % 30 % 40 % Expected life (in years) 3.0 2.9 2.8 Expected dividend yield — % — % — %

Other Operating Expenses (Table

Other Operating Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
Schedule of Other Operating Cost and Expense, by Component	The following tables summarize OOE by program in each of the preceding three years (in thousands): 2021 2020 2019 Operational excellence initiatives $ 3,893 $ 2,791 $ — Strategic reorganization and alignment 911 686 5,812 Manufacturing alignment to support growth — 241 2,145 Acquisition and integration costs (adjustments) 2,544 (776) 377 Other general expenses 508 4,679 3,817 Total other operating expenses $ 7,856 $ 7,621 $ 12,151
Schedule of Restructuring Reserve by Type of Cost	The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Consolidated Balance Sheets, related to the initiatives described above (in thousands): Operational excellence initiatives Strategic reorganization and alignment Total December 31, 2020 $ 291 $ — $ 291 Charges incurred, net of reversals 3,893 911 4,804 Cash payments (3,886) (777) (4,663) December 31, 2021 $ 298 $ 134 $ 432

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Income from continuing operations before taxes for fiscal years 2021, 2020 and 2019 consisted of the following (in thousands): 2021 2020 2019 U.S. $ 48,293 $ 35,337 $ 40,203 International 52,770 50,870 64,990 Total income from continuing operations before taxes $ 101,063 $ 86,207 $ 105,193
Schedule of Components of Income Tax Expense (Benefit)	The provision for income taxes from continuing operations for fiscal years 2021, 2020 and 2019 comprises the following (in thousands): 2021 2020 2019 Current: Federal $ 9,511 $ 7,784 $ 14,090 State 1,553 1,233 87 International 8,459 6,898 10,083 19,523 15,915 24,260 Deferred: Federal (8,665) (4,648) (8,813) State (393) (1,245) 332 International (2,422) (1,073) (1,804) (11,480) (6,966) (10,285) Total provision for income taxes $ 8,043 $ 8,949 $ 13,975
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes from continuing operations differs from the U.S. statutory rate for fiscal years 2021, 2020 and 2019 due to the following: 2021 2020 2019 Statutory rate $ 21,223 21.0 % $ 18,103 21.0 % $ 22,091 21.0 % Federal tax credits (including R&D) (11,929) (11.8) (7,009) (8.1) (4,797) (4.6) Foreign rate differential (5,165) (5.1) (5,333) (6.2) (5,479) (5.2) Stock-based compensation (1,084) (1.1) (1,459) (1.7) (2,422) (2.3) Uncertain tax positions 18 — 1,208 1.4 (920) (0.9) State taxes, net of federal benefit 1,183 1.2 553 0.6 1,106 1.1 U.S. tax on foreign earnings, net of §250 deduction 1,913 1.9 3,216 3.7 5,201 4.9 Valuation allowance 524 0.5 (345) (0.4) (1,606) (1.5) Other 1,360 1.4 15 0.1 801 0.8 Effective tax rate $ 8,043 8.0 % $ 8,949 10.4 % $ 13,975 13.3 %
Schedule of Deferred Tax Assets and Liabilities	The net deferred tax liability consists of the following (in thousands): December 31, December 31, Tax credit carryforwards $ 11,394 $ 13,449 Inventories 14,147 14,099 Net operating loss carryforwards 11,721 10,436 Operating lease liabilities 17,950 11,969 Stock-based compensation 3,724 3,276 Accrued expenses 9,348 8,058 Gross deferred tax assets 68,284 61,287 Less valuation allowance (19,456) (20,739) Net deferred tax assets 48,828 40,548 Property, plant and equipment (7,354) (5,824) Intangible assets (186,150) (197,048) Operating lease assets (17,974) (11,290) Other (3,144) (4,292) Gross deferred tax liabilities (214,622) (218,454) Net deferred tax liability $ (165,794) $ (177,906) Presented as follows: Noncurrent deferred tax asset $ 5,711 $ 4,398 Noncurrent deferred tax liability (171,505) (182,304) Net deferred tax liability $ (165,794) $ (177,906)
Schedule of Operating Loss and Tax Credit Carryforwards	As of December 31, 2021, the Company has the following carryforwards available: Jurisdiction Tax Amount Begin to Expire U.S. State Net operating losses (1) $ 120.7 2022 International Net operating losses (1) 12.2 2022 U.S. Federal Foreign tax credits 6.7 2022 U.S. State R&D tax credits 1.4 2022 U.S. State State tax credits 4.9 2022 __________ (1) Net operating losses (“NOLs”) are presented as pre-tax amounts.
Schedule of Income Tax Contingencies	Below is a summary of changes to the unrecognized tax benefit for fiscal years 2021, 2020 and 2019 (in thousands): 2021 2020 2019 Balance, beginning of year $ 5,484 $ 4,446 $ 5,369 Additions based upon tax positions related to the current year 3,324 300 300 Additions (reductions) related to prior period tax returns (3,271) 738 (1,223) Balance, end of year $ 5,537 $ 5,484 $ 4,446

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability for fiscal years 2021 and 2020 comprises the following (in thousands): 2021 2020 Beginning balance $ 163 $ 1,933 Additions to warranty reserve, net of reversals (15) (156) Adjustments to pre-existing warranties (71) (119) Warranty claims settled — (1,495) Acquisitions $ 432 — Ending balance $ 509 $ 163

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Schedule of Lease Term, Discount Rate, Lease Costs and Supplemental Cash Flow Information	The components and classification of lease cost are as follows (in thousands): December 31, December 31, Finance lease cost: Amortization of lease assets $ 223 $ 7 Interest on lease liabilities 59 1 Finance lease cost 282 8 Operating lease cost 10,729 10,425 Short-term lease cost (leases with initial term of 12 months or less) 137 86 Variable lease cost 2,619 2,615 Sublease income (1,392) (1,495) Total lease cost $ 12,375 $ 11,639 Cost of sales $ 9,642 $ 9,141 SG&A 1,817 1,803 RD&E 857 694 Interest expense $ 59 $ 1 Total lease cost $ 12,375 $ 11,639 The following table presents the weighted average remaining lease term and discount rate. December 31, December 31, Weighted-average remaining lease term - operating leases (in years) 7.0 7.0 Weighted-average remaining lease term - finance leases (in years) 12.2 3.8 Weighted-average discount rate - operating leases 3.9 % 5.3 % Weighted-average discount rate - finance leases 3.5 % 2.2 % Supplemental cash flow information related to leases for fiscal years 2021 and 2020 is as follows (in thousands): 2021 2020 Cash paid for operating leases $ 10,808 $ 10,385 Cash paid for interest on finance leases 59 1 Assets acquired under operating leases 32,466 9,059 Assets acquired under finance leases 8,154 127
Schedule of Operating Lease Liability Maturities (Topic 842)	At December 31, 2021, the maturities of operating and finance lease liabilities were as follows (in thousands): Operating Leases Finance Leases 2022 $ 12,423 $ 876 2023 11,317 888 2024 10,809 896 2025 10,634 787 2026 9,856 640 Thereafter 25,652 5,807 Gross lease liabilities 80,691 9,894 Less: imputed interest (11,062) (1,836) Present value of lease liabilities 69,629 8,058 Less: current portion of lease liabilities (9,862) (608) Total long-term lease liabilities $ 59,767 $ 7,450

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth a reconciliation of the information used in computing basic and diluted EPS for fiscal years 2021, 2020 and 2019 (in thousands, except per share amounts): 2021 2020 2019 Numerator for basic and diluted EPS: Income from continuing operations $ 93,020 $ 77,258 $ 91,218 Income from discontinued operations 3,788 — 5,118 Net income $ 96,808 $ 77,258 $ 96,336 Denominator for basic EPS: Weighted average shares outstanding 32,993 32,845 32,627 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 265 268 410 Denominator for diluted EPS 33,258 33,113 33,037 Basic earnings per share: Income from continuing operations $ 2.82 $ 2.35 $ 2.80 Income from discontinued operations 0.11 — 0.16 Basic earnings per share 2.93 2.35 2.95 Diluted earnings per share: Income from continuing operations $ 2.80 $ 2.33 $ 2.76 Income from discontinued operations 0.11 — 0.15 Diluted earnings per share 2.91 2.33 2.92
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities for fiscal years 2021, 2020 and 2019, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): 2021 2020 2019 Time-vested stock options, restricted stock and restricted stock units 4 98 30 Performance-vested restricted stock units 92 89 47

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Changes in Number of Shares of Common Stock	The following table sets forth the changes in the number of shares of common stock for fiscal years 2021 and 2020: Issued Treasury Stock Outstanding Shares outstanding at December 31, 2019 32,847,017 (146,546) 32,700,471 Stock options exercised 27,544 74,596 102,140 Vesting of RSUs, net of shares withheld to cover taxes 33,617 71,950 105,567 Shares outstanding at December 31, 2020 32,908,178 — 32,908,178 Stock options exercised 34,233 — 34,233 Vesting of RSUs, net of shares withheld to cover taxes 120,925 — 120,925 Shares outstanding at December 31, 2021 33,063,336 — 33,063,336
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive income comprises the following (in thousands): Defined Cash Foreign Total Tax Net-of-Tax December 31, 2019 $ (912) $ (2,358) $ 22,639 $ 19,369 $ 619 $ 19,988 Unrealized loss on cash flow hedges — (6,683) — (6,683) 1,404 (5,279) Realized loss on foreign currency hedges — 638 — 638 (134) 504 Realized loss on interest rate swap hedges — 3,447 — 3,447 (724) 2,723 Net defined benefit plan adjustments (183) — — (183) 32 (151) Foreign currency translation gain — — 34,907 34,907 — 34,907 December 31, 2020 $ (1,095) $ (4,956) $ 57,546 $ 51,495 $ 1,197 $ 52,692 Unrealized gain on cash flow hedges — 91 — 91 (19) 72 Realized gain on foreign currency hedges — (832) — (832) 175 (657) Realized loss on interest rate swap hedges — 3,406 — 3,406 (716) 2,690 Net defined benefit plan adjustments 205 — — 205 14 219 Foreign currency translation loss — — (27,826) (27,826) — (27,826) December 31, 2021 $ (890) $ (2,291) $ 29,720 $ 26,539 $ 651 $ 27,190

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Significant Significant December 31, 2021 Assets: Foreign currency hedging contracts $ 687 $ — $ 687 $ — Liabilities: Interest rate swap 2,978 — 2,978 — Liabilities: Contingent consideration 2,415 — — 2,415 December 31, 2020 Assets: Foreign currency hedging contracts $ 2,070 $ — $ 2,070 $ — Liabilities: Interest rate swaps 7,026 — 7,026 — Liabilities: Contingent consideration 3,900 — — 3,900 Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of December 31, 2021 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 150,000 Jun 2020 Jun 2023 2.1785 % 0.1013 % $ (2,978) Other long-term liabilities (17.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands): Notional Amount Maturity Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun 2023 2.1785 % 0.1480 % $ (7,026) Other long-term liabilities Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2021 is as follows (dollars in thousands): Notional Amount Maturity $/Foreign Currency Fair Value Balance Sheet Location $ 22,201 Dec 2022 0.0463 MXN Peso $ 408 Prepaid expenses and other current assets 17,017 Dec 2022 1.1344 Euro 130 Prepaid expenses and other current assets 9,020 Dec 2022 0.0220 UYU Peso 149 Prepaid expenses and other current assets Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands): Notional Amount Maturity $/Foreign Currency Fair Value Balance Sheet Location $ 16,132 Sep 2021 1.1949 Euro $ 399 Prepaid expenses and other current assets 10,224 Sep 2021 0.0454 MXN Peso 922 Prepaid expenses and other current assets 2,656 Mar 2021 0.0443 MXN Peso 341 Prepaid expenses and other current assets 7,269 Dec 2021 0.0485 MXN Peso 77 Prepaid expenses and other current assets 3,252 Aug 2021 0.0232 UYU Peso 165 Prepaid expenses and other current assets 3,966 Nov 2021 0.0227 UYU Peso 166 Prepaid expenses and other current assets
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	The following table presents the impact of cash flow hedge derivative instruments on other comprehensive income (“OCI”), AOCI and the Company’s Consolidated Statement of Operations for fiscal years 2021, 2020 and 2019 (in thousands): Gain (Loss) Recognized in OCI Gain (Loss) Reclassified from AOCI Derivative 2021 2020 2019 Location in Statement of Operations 2021 2020 2019 Interest rate swaps $ 642 $ (7,405) $ (5,618) Interest expense $ (3,406) $ (3,447) $ 1,621 Foreign exchange contracts (943) 1,017 (1,044) Sales (674) 618 (1,334) Foreign exchange contracts 399 (355) 2,634 Cost of sales 1,437 (1,177) 1,482 Foreign exchange contracts (7) 60 — Operating expenses 69 (79) —
Schedule of Rollforward of Contingent Consideration	The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for fiscal years 2021 and 2020 (in thousands): December 31, 2019 $ 4,200 Amount recorded for current year acquisitions 2,700 Fair value measurement adjustment (2,000) Payments (1,000) December 31, 2020 3,900 Fair value measurement adjustment 133 Payments (1,621) Foreign currency translation 3 December 31, 2021 $ 2,415
Schedule of Contingent Consideration Measurement Inputs	The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration: December 31, 2021 Contingency Type Remaining Maximum Payout (undiscounted) Fair Value Valuation Technique Unobservable Inputs Weighted Average or Range Revenue-based payments $ 6,750 $ 2,415 Monte Carlo Revenue volatility 29.0 % Discount rate 1.8 % Projected year(s) of payment 2022-2024 (17.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) December 31, 2020 Contingency Type Remaining Maximum Payout (undiscounted) Fair Value Valuation Technique Unobservable Inputs Weighted Average or Range Revenue-based payments $ 9,000 $ 3,900 Monte Carlo Revenue volatility 35.0 % Discount rate 4.0 % Projected year(s) of payment 2021-2024
Schedule of Equity Method Investments	Equity investments comprise the following (in thousands): December 31, December 31, Equity method investment $ 16,192 $ 21,470 Non-marketable equity securities 5,637 5,723 Total equity investments $ 21,829 $ 27,193 The components of (Gain) loss on equity investments, net for each period were as follows (in thousands): 2021 2020 2019 Equity method investment (income) loss $ 3,057 $ (5,706) $ (1,100) Impairment charges 86 369 1,575 Total (gain) loss on equity investments, net $ 3,143 $ (5,337) $ 475

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Sales by Product Line	The following table presents sales by product line for fiscal years 2021, 2020 and 2019 (in thousands). 2021 2020 2019 Segment sales by product line: Medical Cardio & Vascular $ 626,013 $ 569,948 $ 610,056 Cardiac & Neuromodulation 446,569 346,242 457,194 Advanced Surgical, Orthopedics & Portable Medical 110,044 121,788 132,429 Total Medical 1,182,626 1,037,978 1,199,679 Non-Medical 38,453 35,464 58,415 Total sales $ 1,221,079 $ 1,073,442 $ 1,258,094
Schedule of Sales by Geographic Area	The following table presents sales by significant country for fiscal years 2021, 2020 and 2019. In these tables, sales are allocated based on where the products are shipped (in thousands). 2021 2020 2019 Sales by geographic area: United States $ 671,502 $ 596,804 $ 698,474 Non-Domestic locations: Puerto Rico 110,162 96,048 154,644 Costa Rica 66,975 58,853 63,634 Rest of world 372,440 321,737 341,342 Total sales $ 1,221,079 $ 1,073,442 $ 1,258,094 The following table presents revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped for fiscal years 2021 and 2020. 2021 2020 Ship to Location Medical Non-Medical Medical Non-Medical United States 54% 71% 55% 60% Rest of world 46% 29% 45% 40%
Schedule of Revenue by Major Customers by Reporting Segments	The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues for fiscal years 2021 and 2020. 2021 2020 Customer Medical Non-Medical Medical Non-Medical Customer A 19% * 19% * Customer B 17% * 17% * Customer C 14% * 15% * Customer D * 36% * 22% Customer E * * * 10% All other customers 50% 64% 49% 68% __________ * Less than 10% of segment’s total revenues for the period.
Schedule of Segment Income (Loss) from Operations	The following table presents income from continuing operations for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands). 2021 2020 2019 Segment income from continuing operations: Medical $ 213,600 $ 169,396 $ 223,873 Non-Medical 8,022 4,848 16,289 Total segment income from continuing operations 221,622 174,244 240,162 Unallocated operating expenses (85,911) (53,632) (82,527) Operating income 135,711 120,612 157,635 Unallocated expenses, net (34,648) (34,405) (52,442) Income from continuing operations before taxes $ 101,063 $ 86,207 $ 105,193
Schedule of Segment Depreciation and Amortization	The following table presents depreciation and amortization expense for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands). 2021 2020 2019 Segment depreciation and amortization: Medical $ 75,366 $ 72,338 $ 68,867 Non-Medical 1,167 996 1,039 Total depreciation and amortization included in segment income from continuing operations 76,533 73,334 69,906 Unallocated depreciation and amortization 4,836 5,990 7,989 Total depreciation and amortization $ 81,369 $ 79,324 $ 77,895
Schedule of Long-Lived Tangible Assets and Identifiable Assets by Geographic Area	The following table presents total assets for the Company’s reportable segments as of December 31, 2021 and December 31, 2020 (in thousands). December 31, December 31, Identifiable assets: Medical $ 2,448,123 $ 2,212,489 Non-Medical 56,158 52,682 Total reportable segments 2,504,281 2,265,171 Unallocated assets 77,934 106,686 Total assets $ 2,582,215 $ 2,371,857 The following table presents PP&E by geographic area as of December 31, 2021 and December 31, 2020. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands). December 31, December 31, Long-lived tangible assets by geographic area: United States $ 184,474 $ 170,871 Mexico 33,877 32,723 Ireland 41,501 38,526 Rest of world 17,247 11,844 Total $ 277,099 $ 253,964
Schedule of Expenditures for Tangible Long-Lived Assets, Excluding Acquisitions	The following table presents capital expenditures for the Company’s reportable segments for fiscal years 2021, 2020 and 2019 (in thousands). 2021 2020 2019 Expenditures for tangible long-lived assets: Medical $ 48,364 $ 42,435 $ 44,026 Non-Medical 628 1,038 397 Total reportable segments 48,992 43,473 44,423 Unallocated long-lived tangible assets 4,471 3,359 3,775 Total expenditures $ 53,463 $ 46,832 $ 48,198

Revenue From Contracts With C_2

Revenue From Contracts With Customers (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedules of Concentration of Risk by Reveune and Accounts Receivable	A significant portion of the Company’s sales for fiscal years 2021, 2020 and 2019 and accounts receivable at December 31, 2021 and December 31, 2020 were to three customers as follows: Sales Accounts Receivable 2021 2020 2019 December 31, December 31, Customer A 18% 18% 21% 15% 15% Customer B 16% 16% 17% 19% 19% Customer C 13% 14% 12% 10% 13% 47% 48% 50% 44% 47%
Schedule of Contract Assets and Contract Liabilities	The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands): December 31, December 31, Contract assets $ 64,743 $ 40,218 Contract liabilities 3,776 2,498

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	Income from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands): 2021 2020 2019 Gain on sale of discontinued operations $ — $ — $ (4,974) Other income, net (4,931) — (322) Income from discontinued operations before taxes 4,931 — 5,296 Provision for income taxes 1,143 — 178 Income from discontinued operations $ 3,788 $ — $ 5,118 Cash flow information from discontinued operations for fiscal years 2021, 2020 and 2019 was as follows (in thousands): 2021 2020 2019 Cash used in operating activities $ — $ — $ (78) Cash provided by investing activities — — 4,734

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2021USD ($)segmentcustomer	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Schedule of Assets Useful Life [Line Items]
Number of reportable segments | segment		2
Number of customers | customer		3
Outstanding receivables previously reserved, written off			$ 2.3
Sale of accounts receivable		$ 116.1	73.3
Costs incurred from sale of accounts receivable		$ 0	0
Increase in inventory valuation reserves	$ 19
Description of payment terms		Standard payment terms range from 30 to 90 days and may include a discount for early payment.
Net foreign currency transaction gains (losses)		$ 0.1	$ (1.6)	$ (0.1)
Stock options
Schedule of Assets Useful Life [Line Items]
Contractual life		10 years
Award vesting period		3 years
Restricted Stock And Unit Awards | Director
Schedule of Assets Useful Life [Line Items]
Award vesting period		1 year
Minimum | Restricted Stock And Unit Awards
Schedule of Assets Useful Life [Line Items]
Award vesting period		3 years
Minimum | Patents
Schedule of Assets Useful Life [Line Items]
Intangible asset, useful life		5 years
Minimum | Customer lists
Schedule of Assets Useful Life [Line Items]
Intangible asset, useful life		7 years
Minimum | Other
Schedule of Assets Useful Life [Line Items]
Intangible asset, useful life		1 year
Maximum | Restricted Stock And Unit Awards
Schedule of Assets Useful Life [Line Items]
Award vesting period		4 years
Maximum | Performance Based Restricted Stock And Restricted Stock Units
Schedule of Assets Useful Life [Line Items]
Award vesting period		3 years
Maximum | Patents
Schedule of Assets Useful Life [Line Items]
Intangible asset, useful life		20 years
Maximum | Customer lists
Schedule of Assets Useful Life [Line Items]
Intangible asset, useful life		20 years
Maximum | Other
Schedule of Assets Useful Life [Line Items]
Intangible asset, useful life		20 years
Buildings and building improvements | Minimum
Schedule of Assets Useful Life [Line Items]
Property, plant and equipment, useful life		12 years
Buildings and building improvements | Maximum
Schedule of Assets Useful Life [Line Items]
Property, plant and equipment, useful life		30 years
Manufacturing machinery and equipment | Minimum
Schedule of Assets Useful Life [Line Items]
Property, plant and equipment, useful life		3 years
Manufacturing machinery and equipment | Maximum
Schedule of Assets Useful Life [Line Items]
Property, plant and equipment, useful life		10 years
Office Equipment | Minimum
Schedule of Assets Useful Life [Line Items]
Property, plant and equipment, useful life		3 years
Office Equipment | Maximum
Schedule of Assets Useful Life [Line Items]
Property, plant and equipment, useful life		10 years

Business Acquisition (Acquisiti

Business Acquisition (Acquisition of Assets from Oscor Inc Narrative) (Details) $ in Millions	Dec. 01, 2021USD ($)	Dec. 31, 2021USD ($)$ / €
Measurement Input, Annual Attrition Rate | Customer lists | Valuation, Income Approach
Asset Acquisition, Contingent Consideration [Line Items]
Measurement input | $ / €		0.05
Measurement Input, Royalty Rate | Technology | Valuation, Income Approach | Maximum
Asset Acquisition, Contingent Consideration [Line Items]
Measurement input | $ / €		0.040
Measurement Input, Royalty Rate | Technology | Valuation, Income Approach | Minimum
Asset Acquisition, Contingent Consideration [Line Items]
Measurement input | $ / €		0.045
Measurement Input, Royalty Rate | Tradenames | Valuation, Income Approach
Asset Acquisition, Contingent Consideration [Line Items]
Measurement input | $ / €		0.020
Oscor Inc
Asset Acquisition, Contingent Consideration [Line Items]
Percentage of business acquired	100.00%
Consideration transferred | $	$ 220.4
Cash acquired from acquisition | $	$ 2.6
Inventory adjustments | $		$ 1
Oscor Inc | Office And Manufacturing Facilities
Asset Acquisition, Contingent Consideration [Line Items]
Lease ROU asset, adjustment | $		$ 3.1

Business Acquisition (Allocatio

Business Acquisition (Allocation Of The Provisional Purchase Price ) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 01, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair value of net assets acquired
Goodwill	$ 924,704		$ 859,442	$ 839,617
Oscor Inc
Fair value of net assets acquired
Current assets (excluding inventory)		$ 12,148
Inventory		12,212
Property, plant and equipment		17,977
Goodwill		77,887
Intangible assets		105,300
Operating lease assets		15,142
Other noncurrent assets		695
Current liabilities		(8,875)
Operating lease liabilities		(12,044)
Fair value of net assets acquired		$ 220,442

Business Acquisition (Acquisi_2

Business Acquisition (Acquisition of Assets from InoMec Ltd Narrative) (Details) - USD ($) $ in Thousands	Feb. 19, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill acquired		$ 924,704	$ 859,442	$ 839,617
InoMec Ltd
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred	$ 7,000
Cash paid	5,300
Contingent consideration	1,700
Revenue-based payments	3,500	$ 6,750	$ 9,000
Intangible assets	2,000
Goodwill acquired	4,800
Property, plant and equipment	300
Other noncurrent assets	$ 100
Weighted Average Amortization Period (Years)	5 years 10 months 24 days

Business Acquisition (Acquisi_3

Business Acquisition (Acquisition of Assets from US BioDesign LLC Narrative) (Details) - USD ($) $ in Thousands	Dec. 01, 2021	Feb. 19, 2020	Oct. 07, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill acquired				$ 924,704	$ 859,442	$ 839,617
Acquisition-related adjustments (Note 2)					85
Sales				1,221,079	1,073,442	1,258,094
Acquisition related costs				2,000	900	400
US BioDesign LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred			$ 19,100
Cash paid			14,900
Fair value of contingent consideration			4,200
Revenue-based payments			5,500
Goodwill acquired			10,400
Property, plant and equipment			700
Other noncurrent assets			600
Acquisition-related adjustments (Note 2)					100
Sales				4,800	4,500
US BioDesign LLC | Technology
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Acquired finite lived intangible assets			$ 7,400
Intangible asset, useful life			8 years
Oscor Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred	$ 220,400
Sales				4,700
Acquisition related costs				2,400
InoMec Ltd
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration transferred		$ 7,000
Cash paid		5,300
Revenue-based payments		3,500		6,750	9,000
Goodwill acquired		4,800
Property, plant and equipment		300
Other noncurrent assets		$ 100
Sales				$ 3,500	3,400
Acquisition related costs					$ 1,200
US BioDesign LLC
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales						$ 800

Business Acquisition (Indefinit

Business Acquisition (Indefinite-Lived Intangible Assets) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
Customer lists
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 73.8
Weighted Average Amortization Period (Years)	20 years
Weighted Average Discount Rate	9.50%
Technology
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 15.2
Weighted Average Amortization Period (Years)	15 years
Weighted Average Discount Rate	9.50%
Tradenames
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 16.3
Weighted Average Amortization Period (Years)	20 years
Weighted Average Discount Rate	9.50%

Business Acquisition ( Pro Form

Business Acquisition ( Pro Forma Information) (Details) - Oscor Inc - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Combination and Asset Acquisition [Abstract]
Sales	$ 1,274,148	$ 1,128,137
Income from continuing operations	91,844	67,529
Business Combination, Separately Recognized Transactions [Line Items]
Sales	1,274,148	1,128,137
Income from continuing operations	$ 91,844	$ 67,529

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Non-cash investing and financing activities:
Property, plant and equipment purchases included in accounts payable	$ 5,556	$ 3,597	$ 8,646
Cash paid during the year for:
Interest	24,740	33,933	44,784
Income taxes	$ 19,649	$ 18,477	$ 30,034

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 70,956	$ 72,477
Work-in-process	74,152	58,806
Finished goods	10,591	18,040
Total	$ 155,699	$ 149,323

Property, Plant and Equipment_3

Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 683,404	$ 625,670
Accumulated depreciation	(406,305)	(371,706)
Total	277,099	253,964
Manufacturing machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	352,391	320,807
Buildings and building improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	98,007	102,037
Information technology hardware and software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	72,752	69,969
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	85,931	77,382
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	17,099	16,250
Land and land improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	13,980	11,598
Construction work in process
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	41,813	26,389
Other
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,431	$ 1,238

Property, Plant and Equipment_4

Property, Plant and Equipment, Net (Depreciation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 39,772	$ 38,193	$ 37,819

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Nets (Schedule of Goodwill) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Beginning balance	$ 859,442,000	$ 839,617,000
Acquisition	77,887,000	4,800,000
Acquisition-related adjustments (Note 2)		(85,000)
Foreign currency translation	(12,625,000)	15,110,000
Ending balance	924,704,000	859,442,000
Medical
Goodwill [Roll Forward]
Beginning balance	842,442,000	822,617,000
Acquisition	77,887,000	4,800,000
Acquisition-related adjustments (Note 2)		(85,000)
Foreign currency translation	(12,625,000)	15,110,000
Ending balance	907,704,000	842,442,000
Accumulated impairment loss	0
Non-Medical
Goodwill [Roll Forward]
Beginning balance	17,000,000	17,000,000
Acquisition	0	0
Acquisition-related adjustments (Note 2)		0
Foreign currency translation	0	0
Ending balance	17,000,000	$ 17,000,000
Accumulated impairment loss	$ 0

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net (Schedule of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,073,439	$ 985,386
Accumulated Amortization	(355,917)	(318,450)
Net Carrying Amount	717,522	666,936
Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets (excluding goodwill)	90,288	90,288
Purchased technology, tradenames and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	285,659	257,453
Accumulated Amortization	(164,371)	(152,798)
Net Carrying Amount	121,288	104,655
Customer lists
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	783,618	723,791
Accumulated Amortization	(187,412)	(161,856)
Net Carrying Amount	596,206	561,935
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,162	4,142
Accumulated Amortization	(4,134)	(3,796)
Net Carrying Amount	$ 28	$ 346

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Payments to acquire intangible asset	$ 0	$ 4,607	$ 0
License | Non-Medical | Similar Identifiable Assets Relating To A License To Use Technology
Finite-Lived Intangible Assets [Line Items]
Payments to acquire intangible asset		4,500
Asset acquisition contingent consideration liability paid		1,000
Asset acquisition transaction costs capitalized		100
Fair Value Assigned		$ 4,600
Intangible asset, useful life		11 years
Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets (excluding goodwill)	90,288	$ 90,288
Lake Region Medical | Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets (excluding goodwill)	$ 70,000	$ 20,300

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets, Net (Amortization Expense by categories) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 41,597	$ 41,131	$ 40,076
Cost of sales
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	13,090	12,860	13,111
SG&A
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 28,507	$ 28,271	$ 26,965

Goodwill and Other Intangible_7

Goodwill and Other Intangible Assets, Net (Future Amortization Expense) (Details) $ in Thousands	Dec. 31, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 46,594
2023	48,490
2024	47,576
2025	45,946
2026	43,612
After 2026	$ 485,304

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Payable and Accrued Liabilities [Abstract]
Salaries and benefits	$ 27,733	$ 24,512
Profit sharing and bonuses	18,325	19,204
Contract liabilities	3,776	2,498
Product warranties	509	163	$ 1,933
Accrued interest	76	1,644
Other	6,514	8,822
Total	$ 56,933	$ 56,843

Debt (Schedule of Long-Term Deb

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 02, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Unamortized discount on term loan B and deferred debt issuance costs	$ (7,361)		$ (6,715)
Total debt	828,126		731,258
Current portion of long-term debt	(15,250)		(37,500)
Long-term debt	812,876		693,758
Loans Payable | Secured Debt | Senior secured term loan A
Debt Instrument [Line Items]
Long-term debt, gross	467,062		229,687
Total debt		$ 210,900
Loans Payable | Secured Debt | Senior secured term loan B
Debt Instrument [Line Items]
Long-term debt, gross	349,125		508,286
Total debt		$ 462,300
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	19,300		$ 0
Unamortized discount on term loan B and deferred debt issuance costs	$ (1,200)

Debt (Senior Secured Credit Fac

Debt (Senior Secured Credit Facilities) (Details) - USD ($)	Sep. 02, 2021	Dec. 31, 2021	Sep. 01, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	$ 1,000,000,000
Long-term Debt		$ 828,126,000		$ 731,258,000
Secured Debt | Senior secured term loan A
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	$ 250,000,000
Debt instrument term	5 years
Weighted average interest rate		1.35%
Secured Debt | Senior secured term loan B
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	$ 350,000,000
Debt instrument term	7 years
Discount percent	0.50%
Weighted average interest rate		3.00%
Secured Debt | Loans Payable | Senior secured term loan A
Debt Instrument [Line Items]
Debt instrument increase		$ 220,000,000
Weighted average interest rate		2.04%
Long-term Debt	$ 210,900,000
Secured Debt | Loans Payable | Senior secured term loan B
Debt Instrument [Line Items]
Discount percent	1.00%
Long-term Debt	$ 462,300,000
Revolving Credit Facility
Debt Instrument [Line Items]
Weighted average interest rate		1.35%
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity	$ 400,000,000		$ 1,600,000,000
Debt instrument term	5 years
Outstanding amount		$ 19,300,000

Debt (Revolving Credit Facility

Debt (Revolving Credit Facility) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Sep. 02, 2021	Sep. 01, 2021	Jul. 13, 2020
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity		$ 1,000,000,000
Secured Debt | Swingline Loans | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity				$ 40,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Weighted average interest rate	1.35%
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity		400,000,000	$ 1,600,000,000
Remaining borrowing capacity	$ 375,000,000
Outstanding amount	$ 19,300,000
Unused capacity commitment fee	0.15%
Revolving Credit Facility | Line of Credit | Minimum
Debt Instrument [Line Items]
Unused capacity commitment fee	0.15%
Revolving Credit Facility | Line of Credit | Maximum
Debt Instrument [Line Items]
Unused capacity commitment fee	0.25%
Revolving Credit Facility | Line of Credit | London Interbank Offered Rate One - Month (LIBOR) | Minimum
Debt Instrument [Line Items]
Spread on variable rate	1.25%
Revolving Credit Facility | Line of Credit | London Interbank Offered Rate One - Month (LIBOR) | Maximum
Debt Instrument [Line Items]
Spread on variable rate	2.25%
Revolving Credit Facility | Line of Credit | New Revolving Credit Facility 2015
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity		$ 200,000,000
Revolving Credit Facility | Line of Credit | Senior secured term loan A | London Interbank Offered Rate One - Month (LIBOR)
Debt Instrument [Line Items]
Spread on variable rate	1.00%
Revolving Credit Facility | Line of Credit | Senior secured term loan A | Base Rate | Minimum
Debt Instrument [Line Items]
Spread on variable rate	0.25%
Revolving Credit Facility | Line of Credit | Senior secured term loan A | Base Rate | Maximum
Debt Instrument [Line Items]
Spread on variable rate	1.25%
Revolving Credit Facility | Line of Credit | Senior secured term loan A | Fed Funds Effective Rate Overnight Index Swap Rate
Debt Instrument [Line Items]
Spread on variable rate	0.50%
Standby Letters of Credit
Debt Instrument [Line Items]
Outstanding standby letters of credit	$ 5,700,000

Debt (Term Loan Facilities) (De

Debt (Term Loan Facilities) (Details) - Secured Debt	12 Months Ended
	Dec. 31, 2021
Senior secured term loan B
Debt Instrument [Line Items]
Weighted average interest rate	3.00%
Senior secured term loan B | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Spread on variable rate	2.50%
Interest rate floor	0.50%
Senior secured term loan B | Base Rate
Debt Instrument [Line Items]
Spread on variable rate	1.50%
Senior secured term loan A
Debt Instrument [Line Items]
Weighted average interest rate	1.35%

Debt (Covenants) (Details)

Debt (Covenants) (Details) - Revolving Credit Facility - Secured Debt	12 Months Ended
	Dec. 31, 2021$ / €
Senior secured term loan A
Debt Instrument [Line Items]
Net leverage ratio incremental increase option	5.50
ITGRTerm Loan A T L A Facility
Debt Instrument [Line Items]
Net leverage ratio incremental increase option	5
Interest expense ratio	2.50

Debt (Long-term Debt Maturity S

Debt (Long-term Debt Maturity Schedule) (Details) $ in Thousands	Dec. 31, 2021USD ($)
Debt Disclosure [Abstract]
2022	$ 15,250
2023	18,188
2024	29,938
2025	38,750
2026	401,739
After 2026	$ 331,622

Debt (Deferred Financing Fees)

Debt (Deferred Financing Fees) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred Finance Costs [Roll Forward]
Total, Beginning Balance	$ 6,715
Total, Amortization during the period	(6,954)	$ (4,774)	$ (7,772)
Total, Ending Balance	7,361	6,715
Revolving Credit Facility
Deferred Finance Costs [Roll Forward]
Debt issuance costs, Beginning Balance	891
Financing costs incurred	2,762
Write-off of debt issuance costs and unamortized discount	(72)
Amortization during the period	(542)
Debt issuance costs, Ending Balance	3,039	891
Term Loan And Senior Notes
Deferred Finance Costs [Roll Forward]
Debt issuance costs, Beginning Balance	5,258
Financing costs incurred	5,236
Write-off of debt issuance costs and unamortized discount	(2,677)
Amortization during the period	(2,143)
Debt issuance costs, Ending Balance	5,674	5,258
Total, Beginning Balance	6,715
Total, Financing costs incurred	6,986
Total, Write-off during the period	(3,631)
Total, Amortization during the period	(2,709)
Total, Ending Balance	7,361	6,715
Senior secured term loan B
Deferred Finance Costs [Roll Forward]
Unamortized discount on TLB Facility, Beginning Balance	1,457
Unamortized discount on TLB Facility, Financing costs incurred	1,750
Unamortized discount on TLB Facility, Write-off during the period	(954)
Unamortized discount on TLB Facility, Amortization during the period	(566)
Unamortized discount on TLB Facility, Ending Balance	$ 1,687	$ 1,457

Debt (Deferred Debt Issuance Co

Debt (Deferred Debt Issuance Costs and Discounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Unamortized debt issuance costs	$ 7,361	$ 6,715
Other Assets | Revolving Credit Facility
Debt Instrument [Line Items]
Debt issuance costs	2,800
Loans Payable
Debt Instrument [Line Items]
Debt issuance costs	8,800
Loans Payable | Long-term Debt
Debt Instrument [Line Items]
Debt issuance costs	7,000
Secured Debt | Senior secured term loan B
Debt Instrument [Line Items]
Original issue discount	1,800
Write off of debt issuance cost	300
Secured Debt | Senior secured term loan A
Debt Instrument [Line Items]
Debt issuance costs	1,000
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Unamortized debt issuance costs	1,200
Write off of debt issuance cost	$ 3,300

Benefit Plans (Savings Plan Nar

Benefit Plans (Savings Plan Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution And Benefit Plan Disclosure [Line Items]
Net costs recognized	$ 7,900,000	$ 5,000,000	$ 7,200,000
Maximum
Defined Contribution And Benefit Plan Disclosure [Line Items]
Employer matching contribution, per dollar	$ 0.50
Employer matching contribution, percentage of employees' gross pay	6.00%

Benefit Plans (Defined Benefit

Benefit Plans (Defined Benefit Plans Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Aggregated projected benefit obligation	$ 3.9	$ 3.7
Net periodic pension cost	0.5	$ 0.4	$ 0.3
Expected future benefit payments first five years	1
Expected future benefit payments next five years	$ 1.8

Stock-Based Compensation (Narra

Stock-Based Compensation (Narratives) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	1,450,000
Number of shares available for grant (in shares)	1,636,980
Restricted Stock and Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense tax benefit	$ 1.1	$ 1.5	$ 2.8
Total unrecognized compensation cost	$ 13.9
Period for recognition	1 year 7 months 6 days
Fair value of shares vested	$ 12.9	$ 9.9	$ 2.4
Granted (in dollars per share)	$ 81.98	$ 83.94	$ 82.31
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grants in period (in shares)	0	0
Closing stock price (in dollars per share)	$ 85.59
Performance Based Restricted Stock And Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost	$ 6
Period for recognition	1 year 10 months 24 days
Fair value of shares vested	$ 3.1	$ 2.9	$ 6.7
Granted (in dollars per share)	$ 85.16	$ 95.06	$ 101.17
Performance period (over)	3 years
Illiquidity discount percent	8.19%	8.00%

Stock-Based Compensation (Compo

Stock-Based Compensation (Components of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 16,185	$ 9,163	$ 9,294
Cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	3,365	1,658	1,011
SG&A
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	11,579	6,942	7,827
RD&E
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	969	563	269
OOE
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	272	0	187
Stock options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0	43	410
RSUs and PRSUs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 16,185	$ 9,120	$ 8,884

Stock-Based Compensation (Weigh

Stock-Based Compensation (Weighted-Average Fair Value and Assumptions) (Details) - Performance Based Restricted Stock And Restricted Stock Units - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value(in dollars per share)	$ 85.16	$ 107.27	$ 117.03
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	0.19%	1.29%	2.46%
Expected volatility	41.00%	30.00%	40.00%
Expected life (in years)	3 years	2 years 10 months 24 days	2 years 9 months 18 days
Expected dividend yield	0.00%	0.00%	0.00%

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Option Activity) (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Number of Stock Options
Beginning balance (in shares) | shares	281,873
Exercised (in shares) | shares	(34,233)
Ending balance (in shares) | shares	247,640
Vested and exercisable (in shares) | shares	247,640
Weighted Average Exercise Price
Beginning balance (in dollars per share) | $ / shares	$ 36.05
Exercised (in dollars per share) | $ / shares	21.72
Ending balance (in dollars per share) | $ / shares	38.03
Vested and exercisable (in dollars per share) | $ / shares	$ 38.03
Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value
Outstanding, weighted average remaining contractual term	4 years 2 months 12 days
Vested and exercisable , weighted average remaining contractual term	4 years 2 months 12 days
Outstanding, aggregate intrinsic value | $	$ 11.8
Vested and exercisable , aggregate intrinsic value | $	$ 11.8

Stock-Based Compensation (Exerc

Stock-Based Compensation (Exercise of Stock Option) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Intrinsic value	$ 2,370	$ 4,773	$ 7,998
Cash received	$ 743	$ 3,263	$ 3,242

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock and Restricted Stock Units) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Performance Based Restricted Stock And Restricted Stock Units
Weighted Average Grant Date Fair Value
Granted (in dollars per share)	$ 85.16	$ 95.06	$ 101.17
Restricted Stock And Restricted Stock Units Time Based
Time-Vested and Performance-Vested Restricted Stock Units and Awards
Beginning balance (in shares)	207,923
Granted (in shares)	208,624
Vested (in shares)	(149,464)
Forfeited (in shares)	(18,952)
Ending balance (in shares)	248,131	207,923
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 75.38
Granted (in dollars per share)	81.98
Vested (in dollars per share)	74.47
Forfeited (in dollars per share)	79.84
Ending balance (in dollars per share)	$ 81.14	$ 75.38
Performance Based Restricted Stock And Restricted Stock Units
Time-Vested and Performance-Vested Restricted Stock Units and Awards
Beginning balance (in shares)	219,391
Granted (in shares)	92,384
Vested (in shares)	(38,882)
Forfeited (in shares)	(74,024)
Ending balance (in shares)	198,869	219,391
Weighted Average Grant Date Fair Value
Beginning balance (in dollars per share)	$ 72.33
Granted (in dollars per share)	85.16
Vested (in dollars per share)	37.75
Forfeited (in dollars per share)	53.45
Ending balance (in dollars per share)	$ 92.07	$ 72.33

Other Operating Expenses (Sched

Other Operating Expenses (Schedule of Other Operating Expenses) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Operating Income Expense Detail [Line Items]
Acquisition and integration costs (adjustments)	$ 2,544		$ (776)	$ 377
Other general expenses	508		4,679	3,817
Total other operating expenses	7,856	$ 7,856	7,621	12,151
Operational Excellence Initiatives
Other Operating Income Expense Detail [Line Items]
Restructuring Costs	3,893		2,791	0
Strategic reorganization and alignment
Other Operating Income Expense Detail [Line Items]
Restructuring Costs	911		686	5,812
Manufacturing alignment to support growth
Other Operating Income Expense Detail [Line Items]
Restructuring Costs	$ 0		$ 241	$ 2,145

Other Operating Expenses (Narra

Other Operating Expenses (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 03, 2020
Restructuring Cost and Reserve [Line Items]
Charges incurred, net of reversals	$ 4,804
Acquisition related costs	2,000	$ 900	$ 400
Strategic reorganization and alignment
Restructuring Cost and Reserve [Line Items]
Charges incurred, net of reversals	911
Strategic reorganization and alignment | Medical
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception				$ 23,000
Manufacturing alignment to support growth
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	5,800
Operational Excellence Initiatives Two Thousand Twenty One Initiatives | Employee Severance
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	3,600
Minimum | Employee Severance | Operational Excellence Initiatives Two Thousand Twenty One Initiatives
Restructuring Cost and Reserve [Line Items]
Expected costs	4,000
Maximum | Employee Severance | Operational Excellence Initiatives Two Thousand Twenty One Initiatives
Restructuring Cost and Reserve [Line Items]
Expected costs	5,000
Oscor Inc
Restructuring Cost and Reserve [Line Items]
Acquisition related costs	2,400
InoMec Ltd
Restructuring Cost and Reserve [Line Items]
Acquisition related costs		1,200
Fair value reduction adjustment for acquisition-related contingent consideration liability	100
US BioDesign LLC
Restructuring Cost and Reserve [Line Items]
Fair value reduction adjustment for acquisition-related contingent consideration liability		$ 2,000
Operational excellence initiatives
Restructuring Cost and Reserve [Line Items]
Charges incurred, net of reversals	3,100
Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives
Restructuring Cost and Reserve [Line Items]
Capital investments expended	900
Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives | Minimum
Restructuring Cost and Reserve [Line Items]
Capital investments expended	5,000
Strategic Reorganization And Alignment Initiatives Two Thousand Twenty One Initiatives | Maximum
Restructuring Cost and Reserve [Line Items]
Capital investments expended	$ 8,000

Other Operating Expenses (Chang

Other Operating Expenses (Changes in Accrued Liabilities) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	$ 291
Charges incurred, net of reversals	4,804
Cash payments	(4,663)
Restructuring reserve, ending balance	432
Operational excellence initiatives
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	291
Charges incurred, net of reversals	3,893
Cash payments	(3,886)
Restructuring reserve, ending balance	298
Strategic reorganization and alignment
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	0
Charges incurred, net of reversals	911
Cash payments	(777)
Restructuring reserve, ending balance	$ 134

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Unrecognized tax benefit	$ 5.5
Deferred payroll taxes	4.8	$ 9.7
Payment for employment taxes	$ 4.9

Income Taxes (Income Before Inc

Income Taxes (Income Before Income Tax Domestic And Foreign) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	$ 101,063	$ 86,207	$ 105,193
U.S.
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	48,293	35,337	40,203
International
Income Tax Disclosure [Line Items]
Income (loss) from continuing operations before income taxes	$ 52,770	$ 50,870	$ 64,990

Income Taxes (Provision Benefit

Income Taxes (Provision Benefit of Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 9,511	$ 7,784	$ 14,090
State	1,553	1,233	87
International	8,459	6,898	10,083
Total	19,523	15,915	24,260
Deferred:
Federal	(8,665)	(4,648)	(8,813)
State	(393)	(1,245)	332
International	(2,422)	(1,073)	(1,804)
Total	(11,480)	(6,966)	(10,285)
Total provision for income taxes	$ 8,043	$ 8,949	$ 13,975

Income Taxes (Effect Tax Rate R

Income Taxes (Effect Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory rate	$ 21,223	$ 18,103	$ 22,091
Federal tax credits (including R&D)	(11,929)	(7,009)	(4,797)
Foreign rate differential	(5,165)	(5,333)	(5,479)
Stock-based compensation	(1,084)	(1,459)	(2,422)
Uncertain tax positions	18	1,208	(920)
State taxes, net of federal benefit	1,183	553	1,106
U.S. tax on foreign earnings, net of §250 deduction	1,913	3,216	5,201
Valuation allowance	524	(345)	(1,606)
Other	1,360	15	801
Total provision for income taxes	$ 8,043	$ 8,949	$ 13,975
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory rate	21.00%	21.00%	21.00%
Federal tax credits (including R&D)	(11.80%)	(8.10%)	(4.60%)
Foreign rate differential	(5.10%)	(6.20%)	(5.20%)
Stock-based compensation	(1.10%)	(1.70%)	(2.30%)
Uncertain tax positions	0.00%	1.40%	(0.90%)
State taxes, net of federal benefit	1.20%	0.60%	1.10%
U.S. tax on foreign earnings, net of §250 deduction	1.90%	3.70%	4.90%
Valuation allowance	0.50%	(0.40%)	(1.50%)
Other	1.40%	0.10%	0.80%
Effective tax rate	8.00%	10.40%	13.30%

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Components of Deferred Tax Assets and Liabilities [Abstract]
Tax credit carryforwards	$ 11,394	$ 13,449
Inventories	14,147	14,099
Net operating loss carryforwards	11,721	10,436
Operating lease liabilities	17,950	11,969
Stock-based compensation	3,724	3,276
Accrued expenses	9,348	8,058
Gross deferred tax assets	68,284	61,287
Less valuation allowance	(19,456)	(20,739)
Net deferred tax assets	48,828	40,548
Property, plant and equipment	(7,354)	(5,824)
Intangible assets	(186,150)	(197,048)
Operating lease assets	(17,974)	(11,290)
Other	(3,144)	(4,292)
Gross deferred tax liabilities	(214,622)	(218,454)
Net deferred tax liability	(165,794)	(177,906)
Noncurrent deferred tax asset	5,711	4,398
Noncurrent deferred tax liability	$ (171,505)	$ (182,304)

Income Taxes (Income Tax Carry

Income Taxes (Income Tax Carry Forward) (Details) $ in Millions	Dec. 31, 2021USD ($)
U.S. State
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 120.7
U.S. State | R&D tax credits
Operating Loss Carryforwards [Line Items]
Tax Credit	1.4
U.S. State | State tax credits
Operating Loss Carryforwards [Line Items]
Tax Credit	4.9
International
Operating Loss Carryforwards [Line Items]
Net operating loss	12.2
U.S. Federal | Foreign tax credits
Operating Loss Carryforwards [Line Items]
Tax Credit	$ 6.7

Income Taxes (Unrecognized Tax

Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance, beginning of year	$ 5,484	$ 4,446	$ 5,369
Additions based upon tax positions related to the current year	3,324	300	300
Additions (reductions) related to prior period tax returns	(3,271)	738	(1,223)
Balance, end of year	$ 5,537	$ 5,484	$ 4,446

Commitments and Contingencies_2

Commitments and Contingencies (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Gain Contingencies [Line Items]
Proceeds from legal settlements	$ 28,900
Gain on litigation settlement	$ 28,200		$ 28,200
Loss contingency damages sought		$ 300
Drawn down from the escrow		200
Anticipated future costs remaining		100
Accrued environmental loss contingencies, current		100
Expenses related to license agreements		884,109	787,735	$ 903,084
Self insurance reserve		5,600	5,400
Royalty
Gain Contingencies [Line Items]
Expenses related to license agreements		$ 1,300	$ 1,200	$ 1,400

Commitments and Contingencies_3

Commitments and Contingencies (Change in Product Warranty Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 163	$ 1,933
Additions to warranty reserve, net of reversals	(15)	(156)
Adjustments to pre-existing warranties	(71)	(119)
Warranty claims settled	0	(1,495)
Acquisitions	432	0
Ending balance	$ 509	$ 163

Leases (Narrative) (Details)

Leases (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)facility	Dec. 31, 2020USD ($)
Leases [Abstract]
Gross assets acquired	$ 8.3
Finance lease accumulated amortization	$ 0.2
Finance lease right-of-use asset		$ 0
Number of facilities in which lease terms were extended | facility	3

Leases (Schedule of Lease Costs

Leases (Schedule of Lease Costs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lessor, Lease, Description [Line Items]
Amortization of lease assets	$ 223	$ 7
Finance lease cost	59	1
Finance lease cost	282	8
Operating lease cost	10,729	10,425
Short-term lease cost (leases with initial term of 12 months or less)	137	86
Variable lease cost	2,619	2,615
Sublease income	(1,392)	(1,495)
Total lease cost	12,375	11,639
Cost of sales
Lessor, Lease, Description [Line Items]
Total lease cost	9,642	9,141
SG&A
Lessor, Lease, Description [Line Items]
Total lease cost	1,817	1,803
RD&E
Lessor, Lease, Description [Line Items]
Total lease cost	857	694
Interest expense
Lessor, Lease, Description [Line Items]
Total lease cost	$ 59	$ 1

Leases (Schedule of Operating L

Leases (Schedule of Operating Lease Liability Maturities) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Operating Leases
2022	$ 12,423
2023	11,317
2024	10,809
2025	10,634
2026	9,856
Thereafter	25,652
Gross lease liabilities	80,691
Less: imputed interest	(11,062)
Present value of lease liabilities	$ 69,629
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued Liabilities, Current	Accrued Liabilities, Current
Less: current portion of lease liabilities	$ (9,862)	$ (8,431)
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Operating lease liabilities	$ 59,767	$ 37,861
Finance Leases
2022	876
2023	888
2024	896
2025	787
2026	640
Thereafter	5,807
Gross lease liabilities	9,894
Less: imputed interest	(1,836)
Present value of lease liabilities	8,058
Less: current portion of lease liabilities	(608)
Total long-term lease liabilities	$ 7,450

Leases (Lease Term and Discount

Leases (Lease Term and Discount Rate) (Details)	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term - operating leases (in years)	7 years	7 years
Weighted-average remaining lease term - finance leases (in years)	12 years 2 months 12 days	3 years 9 months 18 days
Weighted-average discount rate - operating leases	3.90%	5.30%
Weighted-average discount rate - finance leases	3.50%	2.20%

Leases (Schedule of Operating_2

Leases (Schedule of Operating Lease Supplemental Cash Flow Information) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Cash paid for operating leases	$ 10,808	$ 10,385
Interest on lease liabilities	59	1
Assets acquired under operating leases	32,466	9,059
Assets acquired under finance leases	$ 8,154	$ 127

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator for basic and diluted EPS:
Income from continuing operations	$ 93,020	$ 77,258	$ 91,218
Income from discontinued operations	3,788	0	5,118
Net income	$ 96,808	$ 77,258	$ 96,336
Denominator for basic EPS:
Weighted average shares outstanding (in shares)	32,993	32,845	32,627
Effect of dilutive securities stock options, restricted stock and restricted stock units (in shares)	265	268	410
Denominator for diluted EPS (in shares)	33,258	33,113	33,037
Basic earnings per share:
Income from continuing operations (in dollars per share)	$ 2.82	$ 2.35	$ 2.80
Income from discontinued operations (in dollars per share)	0.11	0	0.16
Basic earnings per share (in dollars per share)	2.93	2.35	2.95
Diluted earnings per share:
Income from continuing operations (in dollars per share)	2.80	2.33	2.76
Income from discontinued operations (in dollars per share)	0.11	0	0.15
Diluted earnings per share (in dollars per share)	$ 2.91	$ 2.33	$ 2.92

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Time-vested stock options, restricted stock and restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded (in shares)	4	98	30
Performance-vested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded (in shares)	92	89	47

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule of Changes in Number of Shares of Common Stock) (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares outstanding at beginning of year (in shares)	32,908,178
Shares outstanding at beginning of year (in shares)	32,908,178	32,700,471
Stock options exercised (in shares)	34,233	102,140
Shares outstanding at end of year (in shares)	33,063,336	32,908,178
Shares outstanding at beginning of year (in shares)	33,063,336	32,908,178
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares outstanding at beginning of year (in shares)	32,908,178	32,847,017
Stock options exercised (in shares)	34,233	27,544
Shares outstanding at end of year (in shares)	33,063,336	32,908,178
Treasury Stock, Common
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares outstanding at beginning of year (in shares)	0	(146,546)
Stock options exercised (in shares)	0	74,596
Shares outstanding at beginning of year (in shares)	0	0
RSUs
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs, net of shares withheld to cover taxes (in shares)	120,925	105,567
RSUs | Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs, net of shares withheld to cover taxes (in shares)	120,925	33,617
RSUs | Treasury Stock, Common
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of RSUs, net of shares withheld to cover taxes (in shares)	0	71,950

Stockholders' Equity (Schedul_2

Stockholders' Equity (Schedule of Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income [Roll Forward]
Total stockholders’ equity, beginning balance	$ 1,271,055	$ 1,152,488
Total stockholders’ equity, ending balance	1,354,697	1,271,055
Defined Benefit Plan Liability
Accumulated Other Comprehensive Income [Roll Forward]
Total stockholders’ equity, beginning balance	(1,095)	(912)
Reclassification from AOCI, current period, before tax, attributable to parent	205	(183)
Reclassification from AOCI, current period, tax	14	32
Reclassification from AOCI, current period, net of tax, attributable to parent	219	(151)
Total stockholders’ equity, ending balance	(890)	(1,095)
Cash Flow Hedges
Accumulated Other Comprehensive Income [Roll Forward]
Total stockholders’ equity, beginning balance	(4,956)	(2,358)
Reclassification from AOCI, current period, before tax, attributable to parent	91	(6,683)
Reclassification from AOCI, current period, tax	(19)	1,404
Reclassification from AOCI, current period, net of tax, attributable to parent	72	(5,279)
Total stockholders’ equity, ending balance	(2,291)	(4,956)
Cash Flow Hedges | Foreign Exchange Contract
Accumulated Other Comprehensive Income [Roll Forward]
Reclassification from AOCI, current period, before tax, attributable to parent	(832)	638
Reclassification from AOCI, current period, tax	175	(134)
Reclassification from AOCI, current period, net of tax, attributable to parent	(657)	504
Cash Flow Hedges | Interest rate swaps
Accumulated Other Comprehensive Income [Roll Forward]
Reclassification from AOCI, current period, before tax, attributable to parent	3,406	3,447
Reclassification from AOCI, current period, tax	(716)	(724)
Reclassification from AOCI, current period, net of tax, attributable to parent	2,690	2,723
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income [Roll Forward]
Total stockholders’ equity, beginning balance	57,546	22,639
Reclassification from AOCI, current period, before tax, attributable to parent	(27,826)	34,907
Reclassification from AOCI, current period, tax	0	0
Reclassification from AOCI, current period, net of tax, attributable to parent	(27,826)	34,907
Total stockholders’ equity, ending balance	29,720	57,546
Total Pre-Tax Amount
Accumulated Other Comprehensive Income [Roll Forward]
Total stockholders’ equity, beginning balance	51,495	19,369
Total stockholders’ equity, ending balance	26,539	51,495
Tax
Accumulated Other Comprehensive Income [Roll Forward]
Total stockholders’ equity, beginning balance	1,197	619
Total stockholders’ equity, ending balance	651	1,197
Net-of-Tax Amount
Accumulated Other Comprehensive Income [Roll Forward]
Total stockholders’ equity, beginning balance	52,692	19,988
Total stockholders’ equity, ending balance	$ 27,190	$ 52,692

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets: Foreign currency hedging contracts	$ 687	$ 2,070
Liabilities: Interest rate swaps	2,978	7,026
Liabilities: Contingent consideration	2,415	3,900
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets: Foreign currency hedging contracts	0	0
Liabilities: Interest rate swaps	0	0
Liabilities: Contingent consideration	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets: Foreign currency hedging contracts	687	2,070
Liabilities: Interest rate swaps	2,978	7,026
Liabilities: Contingent consideration	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets: Foreign currency hedging contracts	0	0
Liabilities: Interest rate swaps	0	0
Liabilities: Contingent consideration	$ 2,415	$ 3,900

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details) - Designated as Hedging Instrument - Interest Rate Swap Maturing June 2023 - Other long-term liabilities - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Derivatives, Fair Value [Line Items]
Notional Amount	$ 150,000,000	$ 200,000,000
Pay Fixed Rate	2.1785%	2.1785%
Receive Current Floating Rate	0.1013%	0.148%
Fair Value	$ (2,978,000)	$ (7,026,000)

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details) - Prepaid Expenses and Other Current Assets - Designated as Hedging Instrument $ in Thousands	Dec. 31, 2021USD ($)$ / $$ / $	Dec. 31, 2020USD ($)$ / €$ / $$ / $
Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract One
Derivatives, Fair Value [Line Items]
Notional Amount	$ 22,201
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $	0.0463
Fair Value	$ 408
Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Two
Derivatives, Fair Value [Line Items]
Notional Amount	$ 17,017
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $	1.1344
Fair Value	$ 130
Foreign Exchange Contract Maturing December Two Thousand Twenty Two Contract Three
Derivatives, Fair Value [Line Items]
Notional Amount	$ 9,020
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $	0.0220
Fair Value	$ 149
Foreign Exchange Contract Maturing September 2021, Contract One
Derivatives, Fair Value [Line Items]
Notional Amount		$ 16,132
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / €		1.1949
Fair Value		$ 399
Foreign Exchange Contract Maturing September 2021, Contract Two
Derivatives, Fair Value [Line Items]
Notional Amount		$ 10,224
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $		0.0454
Fair Value		$ 922
Foreign Exchange Contract Maturing March 2021
Derivatives, Fair Value [Line Items]
Notional Amount		$ 2,656
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $		0.0443
Fair Value		$ 341
Foreign Exchange Contract Maturing December 2021
Derivatives, Fair Value [Line Items]
Notional Amount		$ 7,269
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $		0.0485
Fair Value		$ 77
Foreign Exchange Contract Maturing August 2021
Derivatives, Fair Value [Line Items]
Notional Amount		$ 3,252
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $		0.0232
Fair Value		$ 165
Foreign Exchange Contract Maturing November 2021
Derivatives, Fair Value [Line Items]
Notional Amount		$ 3,966
Derivative, Forward Exchange Rate (in dollars per Euro and dollars per Mexican Peso) | $ / $		0.0227
Fair Value		$ 166

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements (Schedule of Derivative Instruments with Hedge Accounting Designation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Interest expense
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) Reclassified from AOCI	$ (3,406)	$ (3,447)	$ 1,621
Interest expense | Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) Recognized in OCI	642	(7,405)	(5,618)
Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) Reclassified from AOCI	(674)	618	(1,334)
Sales | Foreign exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) Recognized in OCI	(943)	1,017	(1,044)
Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) Reclassified from AOCI	1,437	(1,177)	1,482
Cost of sales | Foreign exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) Recognized in OCI	399	(355)	2,634
Operating expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) Reclassified from AOCI	69	(79)	0
Operating expenses | Foreign exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (Loss) Recognized in OCI	$ (7)	$ 60	$ 0

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measurements (Narratives) (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 28, 2018
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Gain (loss) reclassification from accumulated OCI to income, estimated net amount to be transferred		$ 1,800,000
Contingent consideration liability, current	$ 1,700,000	900,000	$ 1,700,000
Contingent consideration liability, noncurrent	2,200,000	1,500,000	2,200,000
Non-marketable securities impairment	400,000	100,000
Non-marketable securities fair value	$ 2,200,000	0	2,200,000
Equity method investment, return of capital		2,200,000	$ 400,000	$ 100,000
Foreign Exchange Contract | Not Designated as Hedging Instrument
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Notional amount		15,000,000
Fair value		100,000
Foreign exchange contracts | Not Designated as Hedging Instrument
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Gain (loss) recognized in OCI		$ 400,000
Chinese Venture Capital Fund
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Percentage of ownership interest		6.70%

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 3,900	$ 4,200
Amount recorded for current year acquisitions		2,700
Fair value measurement adjustment	133	(2,000)
Payments	(1,621)	(1,000)
Foreign currency translation	3
Balance at end of period	$ 2,415	$ 3,900

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details) $ in Thousands	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Feb. 19, 2020USD ($)
InoMec Ltd
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Remaining Maximum Payout (undiscounted)	$ 6,750	$ 9,000	$ 3,500
Fair Value, Recurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 2,415	$ 3,900
Fair Value, Recurring | Revenue volatility | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Inputs	0.290	0.350
Fair Value, Recurring | Discount rate | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Inputs	0.018	0.040

Financial Instruments and Fa_10

Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Equity method investment	$ 16,192	$ 21,470
Non-marketable equity securities	5,637	5,723
Total equity investments	21,829	27,193
Equity method investment (income) loss	3,057	(5,706)	$ (1,100)
Impairment charges	86	369	1,575
Total (gain) loss on equity investments, net	$ 3,143	$ (5,337)	$ 475

Segment and Geographic Inform_3

Segment and Geographic Information (Narrative) (Details)	12 Months Ended
	Dec. 31, 2021segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment and Geographic Inform_4

Segment and Geographic Information (Sales by Product Lines) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales	$ 1,221,079	$ 1,073,442	$ 1,258,094
Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales	1,182,626	1,037,978	1,199,679
Medical | Cardio & Vascular
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales	626,013	569,948	610,056
Medical | Cardiac & Neuromodulation
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales	446,569	346,242	457,194
Medical | Advanced Surgical, Orthopedics & Portable Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales	110,044	121,788	132,429
Non-Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales	$ 38,453	$ 35,464	$ 58,415

Segment and Geographic Inform_5

Segment and Geographic Information (Sales by Geographic Information) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 1,221,079	$ 1,073,442	$ 1,258,094
U.S.
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	671,502	596,804	698,474
Puerto Rico
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	110,162	96,048	154,644
Costa Rica
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	66,975	58,853	63,634
Rest of world
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 372,440	$ 321,737	$ 341,342

Segment and Geographic Inform_6

Segment and Geographic Information (Significant Customers) (Details) - Customer Concentration Risk - Sales	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Customer A
Revenue, Major Customer [Line Items]
Concentration risk percentage	18.00%	18.00%	21.00%
Customer B
Revenue, Major Customer [Line Items]
Concentration risk percentage	16.00%	16.00%	17.00%
Customer C
Revenue, Major Customer [Line Items]
Concentration risk percentage	13.00%	14.00%	12.00%
Medical | Customer A
Revenue, Major Customer [Line Items]
Concentration risk percentage	19.00%	19.00%
Medical | Customer B
Revenue, Major Customer [Line Items]
Concentration risk percentage	17.00%	17.00%
Medical | Customer C
Revenue, Major Customer [Line Items]
Concentration risk percentage	14.00%	15.00%
Medical | All other customers
Revenue, Major Customer [Line Items]
Concentration risk percentage	50.00%	49.00%
Non-Medical | Customer D
Revenue, Major Customer [Line Items]
Concentration risk percentage	36.00%	22.00%
Non-Medical | Customer E
Revenue, Major Customer [Line Items]
Concentration risk percentage		10.00%
Non-Medical | All other customers
Revenue, Major Customer [Line Items]
Concentration risk percentage	64.00%	68.00%

Segment and Geographic Inform_7

Segment and Geographic Information (Schedule of Revenue by Ship To Location) (Details) - Sales - Geographic Concentration Risk	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
United States | Medical
Segment Reporting Information [Line Items]
Concentration risk percentage	54.00%	55.00%
United States | Non-Medical
Segment Reporting Information [Line Items]
Concentration risk percentage	71.00%	60.00%
Rest of world | Medical
Segment Reporting Information [Line Items]
Concentration risk percentage	46.00%	45.00%
Rest of world | Non-Medical
Segment Reporting Information [Line Items]
Concentration risk percentage	29.00%	40.00%

Segment and Geographic Inform_8

Segment and Geographic Information (Reconciliation of Segment Information) (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Operating income as reported	$ 135,711	$ 120,612	$ 157,635
Unallocated other income (expense), net	(34,648)	(34,405)	(52,442)
Income from continuing operations before taxes	101,063	86,207	105,193
Total depreciation and amortization	81,369	79,324	77,895
Total assets	2,582,215	2,371,857
Expenditures for tangible long-lived assets, excluding acquisitions	53,463	46,832	48,198
Operating Segments
Segment Reporting Information [Line Items]
Operating income as reported	221,622	174,244	240,162
Total depreciation and amortization	76,533	73,334	69,906
Total assets	2,504,281	2,265,171
Expenditures for tangible long-lived assets, excluding acquisitions	48,992	43,473	44,423
Operating Segments | Medical
Segment Reporting Information [Line Items]
Operating income as reported	213,600	169,396	223,873
Total depreciation and amortization	75,366	72,338	68,867
Total assets	2,448,123	2,212,489
Expenditures for tangible long-lived assets, excluding acquisitions	48,364	42,435	44,026
Operating Segments | Non-Medical
Segment Reporting Information [Line Items]
Operating income as reported	8,022	4,848	16,289
Total depreciation and amortization	1,167	996	1,039
Total assets	56,158	52,682
Expenditures for tangible long-lived assets, excluding acquisitions	628	1,038	397
Unallocated Amount to Segment
Segment Reporting Information [Line Items]
Operating income as reported	(85,911)	(53,632)	(82,527)
Total depreciation and amortization	4,836	5,990	7,989
Total assets	77,934	106,686
Expenditures for tangible long-lived assets, excluding acquisitions	$ 4,471	$ 3,359	$ 3,775

Segment and Geographic Inform_9

Segment and Geographic Information (Long lived Tangible Assets by Region) (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	$ 277,099	$ 253,964
United States
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	184,474	170,871
Mexico
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	33,877	32,723
Ireland
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	41,501	38,526
Rest of world
Segment Reporting, Asset Reconciling Item [Line Items]
Long-lived tangible assets	$ 17,247	$ 11,844

Revenue From Contracts With C_3

Revenue From Contracts With Customers (Disaggregated Revenue) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Percent of revenue from contract with customer compared to total revenue	33.00%	29.00%
Sales | Customer Concentration Risk | Customer A
Disaggregation of Revenue [Line Items]
Concentration risk percentage	18.00%	18.00%	21.00%
Sales | Customer Concentration Risk | Customer B
Disaggregation of Revenue [Line Items]
Concentration risk percentage	16.00%	16.00%	17.00%
Sales | Customer Concentration Risk | Customer C
Disaggregation of Revenue [Line Items]
Concentration risk percentage	13.00%	14.00%	12.00%
Sales | Customer Concentration Risk | Top Customers
Disaggregation of Revenue [Line Items]
Concentration risk percentage	47.00%	48.00%	50.00%
Accounts Receivable | Customer Concentration Risk | Customer A
Disaggregation of Revenue [Line Items]
Concentration risk percentage	15.00%	15.00%
Accounts Receivable | Customer Concentration Risk | Customer B
Disaggregation of Revenue [Line Items]
Concentration risk percentage	19.00%	19.00%
Accounts Receivable | Customer Concentration Risk | Customer C
Disaggregation of Revenue [Line Items]
Concentration risk percentage	10.00%	13.00%
Accounts Receivable | Customer Concentration Risk | Top Customers
Disaggregation of Revenue [Line Items]
Concentration risk percentage	44.00%	47.00%

Revenue From Contracts With C_4

Revenue From Contracts With Customers (Contract Balances) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract assets	$ 64,743	$ 40,218
Contract liabilities	3,776	2,498
Increase in contract assets	24,500
Contract with customer, liability, revenue recognized	$ 1,900	$ 1,300

Discontinued Operations (AS&O B

Discontinued Operations (AS&O Business Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of discontinued operations, gross		$ 4.8
Discontinued Operations, Held-for-sale | AS&O Product Line
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued operation, gain (loss) on disposal of discontinued operation, net of tax	$ 4.9

Discontinued Operations (Income

Discontinued Operations (Income from Discontinued Operations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations before taxes	$ 4,931	$ 0	$ 5,296
Provision for income taxes	1,143	0	178
Income from discontinued operations	3,788	0	5,118
AS&O Product Line | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on sale of discontinued operations	0	0	(4,974)
Other income, net	(4,931)	0	(322)
Income from discontinued operations before taxes	4,931	0	5,296
Provision for income taxes	1,143	0	178
Income from discontinued operations	$ 3,788	$ 0	$ 5,118

Discontinued Operations (Cash F

Discontinued Operations (Cash Flow Information from Discontinued Operations) (Details) - AS&O Product Line - Discontinued Operations, Held-for-sale - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash used in operating activities	$ 0	$ 0	$ (78)
Cash provided by investing activities	$ 0	$ 0	$ 4,734

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense, customer bankruptcy			$ 2,300
Provision for credit losses
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 155	$ 2,443	592
Charged to Costs & Expenses	20	28	1,884
Charged to Other Accounts- Describe	0	0	2
Deductions	(43)	(2,316)	(35)
Balance at end of period	132	155	2,443
Valuation allowance for deferred tax assets
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	20,739	22,229	34,339
Charged to Costs & Expenses	(941)	(275)	736
Charged to Other Accounts- Describe	26	0	0
Deductions	(368)	(1,215)	(12,846)
Balance at end of period	$ 19,456	$ 20,739	$ 22,229

Uncategorized Items - gb-202112

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-02 [Member]